<report>
    <testName>Guardant360</testName>
    <accessionId>A37144</accessionId>
    <patient>
        <lastName>Johnson</lastName>
        <firstName>Robert</firstName>
        <gender>Male</gender>
        <dob>1970-01-01</dob>
    </patient>
    <physician>
        <lastName>Smith</lastName>
        <firstName>Dr. Mary</firstName>
        <npi>UQ</npi>
        <phone>(111) 111-1111</phone>
        <fax>(888) 974-3986</fax>
    </physician>
    <client>
        <name>Demo-Pleasantville Oncology</name>
        <phone>(111) 111-1111</phone>
        <fax>(888) 974-3986</fax>
        <address>
            <address1>123 Main Street</address1>
            <address2></address2>
            <city>Anytown</city>
            <state>CA - California</state>
            <country>United States</country>
            <postalCode>99999</postalCode>
        </address>
    </client>
    <specimen>Blood</specimen>
    <barcode>20099439</barcode>
    <sampleId>A3714401</sampleId>
    <disease>
        <name>Lung adenocarcinoma</name>
        <classification>
            <name>NSCLC</name>
            <associatedGenes>
                <associatedGene>EGFR/(T790M and others)</associatedGene>
                <associatedGene>ALK</associatedGene>
                <associatedGene>ROS1</associatedGene>
                <associatedGene>BRAF</associatedGene>
                <associatedGene>MET</associatedGene>
                <associatedGene>ERBB2/(HER2)</associatedGene>
                <associatedGene>RET</associatedGene>
            </associatedGenes>
        </classification>
    </disease>
    <icdCodes>
        <icdCode>C34.91</icdCode>
    </icdCodes>
    <alterations>
        <alteration>
            <type>snv</type>
            <gene>EGFR</gene>
            <name>T790M</name>
            <method>substitution</method>
            <detected>true</detected>
            <value>1.5%</value>
            <snv>
                <cfdnaPercentage>1.5</cfdnaPercentage>
                <exon>20</exon>
                <cdna>c.2369C>T</cdna>
                <chromosome>7</chromosome>
                <aminoAcidMutation>T790M</aminoAcidMutation>
                <nucleotideMutation>C>T</nucleotideMutation>
                <position>55249071</position>
                <transcriptId>NM_005228.3</transcriptId>
                <reportingCategory>protein_coding</reportingCategory>
            </snv>
            <treatment>
                <approvedTherapies>Osimertinib</approvedTherapies>
                <therapeuticResistance>Afatinib, Erlotinib, Gefitinib</therapeuticResistance>
                <trialAvailable>true</trialAvailable>
                <therapies>
                    <therapy>
                        <drug>Neratinib</drug>
                        <tradeName></tradeName>
                        <rationale>Egfr/Her2/ErbB4 inhibitor.</rationale>
                        <disease>Non-small cell lung carcinoma (NSCLC)</disease>
                        <status>Phase 2</status>
                        <otherDiseases>---
- Breast carcinoma
</otherDiseases>
                        <otherStatus>Phase 3</otherStatus>
                    </therapy>
                    <therapy>
                        <drug>Pyrotinib</drug>
                        <tradeName></tradeName>
                        <rationale>Egfr/Her2 kinase inhibitor.</rationale>
                        <disease>Non-small cell lung carcinoma (NSCLC)</disease>
                        <status>Phase 2</status>
                        <otherDiseases>---
- Breast carcinoma
</otherDiseases>
                        <otherStatus>Phase 3</otherStatus>
                    </therapy>
                    <therapy>
                        <drug>TH4000</drug>
                        <tradeName></tradeName>
                        <rationale>Hypoxia-activated Egfr tyrosine kinase inhibitor.</rationale>
                        <disease>Non-small cell lung carcinoma (NSCLC)</disease>
                        <status>Phase 2</status>
                        <otherDiseases>---
- Head and neck squamous cell carcinoma (HNSCC)
</otherDiseases>
                        <otherStatus>Phase 2</otherStatus>
                    </therapy>
                    <therapy>
                        <drug>Osimertinib</drug>
                        <tradeName>Tagrisso</tradeName>
                        <rationale>Egfr T790M inhibitor.</rationale>
                        <disease>Non-small cell lung carcinoma (NSCLC)</disease>
                        <status>Phase 2</status>
                        <otherDiseases>---
- EGFR-mutant NSCLC
</otherDiseases>
                        <otherStatus>FDA Approved</otherStatus>
                    </therapy>
                    <therapy>
                        <drug>EGF816</drug>
                        <tradeName></tradeName>
                        <rationale>Third generation EGFR mutant-selective (T790M, L858R, exon 19 deletion) tyrosine kinase inhibitor.</rationale>
                        <disease>Non-small cell lung carcinoma (NSCLC)</disease>
                        <status>Phase 2</status>
                        <otherStatus></otherStatus>
                    </therapy>
                    <therapy>
                        <drug>AP32788</drug>
                        <tradeName></tradeName>
                        <rationale>Egfr/Her2 mutant-selective inhibitor.</rationale>
                        <disease>Non-small cell lung carcinoma (NSCLC)</disease>
                        <status>Phase 2</status>
                        <otherStatus></otherStatus>
                    </therapy>
                    <therapy>
                        <drug>Varlitinib</drug>
                        <tradeName></tradeName>
                        <rationale>Egfr/Her2 inhibitor.</rationale>
                        <disease></disease>
                        <status></status>
                        <otherDiseases>---
- Gastric carcinoma
- Pancreatic carcinoma
</otherDiseases>
                        <otherStatus>Phase 2</otherStatus>
                    </therapy>
                    <therapy>
                        <drug>ASP8273</drug>
                        <tradeName></tradeName>
                        <rationale>EGFR mutant-specific inhibitor.</rationale>
                        <disease>Non-small cell lung carcinoma (NSCLC)</disease>
                        <status>Phase 3</status>
                        <otherDiseases>---
- Solid Tumor
</otherDiseases>
                        <otherStatus>Phase 1</otherStatus>
                    </therapy>
                    <therapy>
                        <drug>PF-06747775</drug>
                        <tradeName></tradeName>
                        <rationale>EGFR T790M-specific inhibitor.</rationale>
                        <disease>Non-small cell lung carcinoma (NSCLC)</disease>
                        <status>Phase 1</status>
                        <otherStatus></otherStatus>
                    </therapy>
                    <therapy>
                        <drug>KBP-5209</drug>
                        <tradeName></tradeName>
                        <rationale>ErbB family inhibitor.</rationale>
                        <disease>Solid Tumor</disease>
                        <status>Phase 1</status>
                        <otherStatus></otherStatus>
                    </therapy>
                    <therapy>
                        <drug>Dacomitinib</drug>
                        <tradeName></tradeName>
                        <rationale>Pan-ErbB family tyrosine kinase inhibitor.</rationale>
                        <disease>Non-small cell lung carcinoma (NSCLC)</disease>
                        <status>Phase 3</status>
                        <otherDiseases>---
- Gastric carcinoma
- Glioblastoma
- Glioma
- Pancreatic carcinoma
- Head and neck carcinoma
- Cutaneous squamous cell carcinoma
- Esophageal carcinoma
- Penile carcinoma
- Colorectal carcinoma (CRC)
</otherDiseases>
                        <otherStatus>Phase 2</otherStatus>
                    </therapy>
                    <therapy>
                        <drug>Icotinib</drug>
                        <tradeName>Conmana</tradeName>
                        <rationale>Egfr inhibitor.</rationale>
                        <disease>Non-small cell lung carcinoma (NSCLC)</disease>
                        <status>Phase 3</status>
                        <otherDiseases>---
- Esophageal carcinoma
</otherDiseases>
                        <otherStatus>Phase 2</otherStatus>
                    </therapy>
                </therapies>
                <clinicalRelevances>
                    <clinicalRelevance>
                        <roleInDisease>The presence of an EGFR abnormality (mutation, amplification, or overexpression) can result in an overabundance or overactivity of Egfr protein, which can lead to excessive proliferation (Ciardiello and Tortora, 2008; 18337605). The EGFR T790M mutation has typically been reported as a secondary resistance mutation to the Egfr inhibitors erlotinib, gefitinib and afatinib, but has also been reported as a rare germline variant in de novo non-small cell lung cancer, particularly in lung adenocarcinoma (Wu et al., 2011; 21531810, Yang et al., 2015; 26051236). Several studies have reported the presence of the T790M mutation in the germline in 0-1% of NSCLC cases, although one study did detect this mutation in 50% (5/10) of cases; in addition, T790M was associated with a 31% risk of lung cancer in never smokers in one study (Gazdar et al., 2014; 24736066, Girard et al., 2010; 20068085, Vikis et al., 2007; 17510392, Rosell et al., 2011; 21233402). EGFR mutations in NSCLC have been reported to occur more frequently in women, never-smokers, and in patients with adenocarcinoma histology (Rizzo et al., 2016; 25956936, Lee et al., 2015; 26359571, Naderi et al., 2015; 26362141, Zhou et al., 2016; 27039821, Lee et al., 2016; 26992209, Zhang et al., 2016; 27738317).</roleInDisease>
                        <drugSensitivity>The presence of a sensitizing EGFR mutation in a tumor is the strongest biological predictor of sensitivity to an Egfr tyrosine kinase inhibitor (TKI). Compared with conventional chemotherapy, Egfr TKIs have been shown to improve progression-free survival in non-small cell lung cancer patients whose tumors harbor EGFR mutations (Mok et al., 2009; 19692680, Rosell et al., 2009; 19692684, Tsao et al., 2005; 16014883, Rosell et al., 2012; 22285168). The EGFR T790M mutation reported here has been described as a "gatekeeper" mutation that confers resistance to the tyrosine kinase inhibitors erlotinib and gefitinib (Suda et al., 2009; 19096299, Yun et al., 2008; 18227510). Studies have also reported the emergence of EGFR T790M upon resistance to afatinib monotherapy (Wu et al., 2016; 26862733, Yang et al., 2015; 26051236, Kim et al., 2012; 22228822). Third generation irreversible Egfr TKIs that target the EGFR T790M mutation have shown efficacy in T790M-mutant NSCLC and are under clinical investigation, including osimertinib, which has received FDA-approval for the treatment of EGFR T790M-mutant metastatic NSCLC (Jänne et al., 2011; 21220471, Jänne et al., 2015; 25923549, Greig, 2016; 26729184, Yang et al., 2016; 27198353, Wang et al., 2016; 27071706).</drugSensitivity>
                        <drugResistance>Some patients with EGFR-mutant NSCLC exhibit resistance to Egfr inhibition; resistance has been associated with insertions in EGFR exon 20, the T790M mutation in EGFR, and amplification of the gene MET (Engelman et al., 2007; 17463250, Greulich et al., 2005; 16187797, Kwak et al., 2005; 15897464). Several studies have reported that resistance to Egfr TKIs in NSCLC is mediated by the transformation of NSCLC cell types to those of SCLC with neuroendocrine features (Watanabe et al., 2013; 24012411, Chang et al., 2013; 24101933, Popat et al., 2013; 23312887, Sequist et al., 2011; 21430269).</drugResistance>
                    </clinicalRelevance>
                </clinicalRelevances>
                <biologicalSignificances>
                    <biologicalSignificance>
                        <content>EGFR-T790M is an activating mutation. EGFR activating mutations or amplification may predict sensitivity to Egfr-targeted therapies, including inhibitors of multiple ErbB family members, and several have received FDA approval in some tumor types (Mok et al., 2009; 19692680, Rosell et al., 2009; 19692684, Tsao et al., 2005; 16014883). Egfr activation or overexpression may also lead to activation of the PI3K and MAPK pathway and may confer sensitivity to PI3K and MAPK pathway inhibitors (Bancroft et al., 2002; 11992543). EGFR T790M has been reported to confer resistance to the first generation Egfr TKIs erlotinib and gefitinib, and to the irreversible Egfr inhibitor afatinib as a single agent therapy (Li et al., 2007; 17613438, Yang et al., 2015; 26051236, Wu et al., 2016; 26862733, Kim et al., 2012; 22228822). Third generation irreversible Egfr TKIs that target the EGFR T790M mutation have shown efficacy in T790M-mutant NSCLC and are under clinical investigation, including osimertinib, which has received FDA-approval for the treatment of EGFR T790M-mutant metastatic NSCLC (Jänne et al., 2011; 21220471, Jänne et al., 2015; 25923549, Greig, 2016; 26729184, Yang et al., 2016; 27198353, Wang et al., 2016; 27071706).</content>
                        <molecularFunction>EGFR T790M is a missense alteration located within the kinase domain of the Egfr protein and has been shown to result in activation of Egfr (Sutto and Gervasio, 2013; 23754386, Dixit and Verkhivker, 2009; 19714203, Yun et al., 2008; 18227510). This mutation has been described as a "gatekeeper" mutation that confers resistance to the tyrosine kinase inhibitors erlotinib and gefitinib (Suda et al., 2009; 19096299, Yun et al., 2008; 18227510). Studies have also reported the emergence of EGFR T790M upon resistance to afatinib monotherapy (Wu et al., 2016; 26862733, Yang et al., 2015; 26051236, Kim et al., 2012; 22228822).</molecularFunction>
                        <incidence>EGFR mutations have been reported in 37% (14530/39587) of Lung adenocarcinoma samples analyzed in COSMIC (Apr 2017). EGFR mutations have been reported in 5.9-18% of Lung adenocarcinoma samples (cBioPortal for Cancer Genomics, Apr 2017). EGFR mutations have been reported in 14-49% of NSCLC cases, and found to be more common in East Asian patients as compared with other ethnicities (Vallee et al., 2013; 23934203, Rizzo et al., 2016; 25956936, Arrieta et al., 2015; 26358312, Zhou et al., 2016; 27039821, Lee et al., 2016; 26992209, Zhang et al., 2016; 27738317).</incidence>
                    </biologicalSignificance>
                </biologicalSignificances>
                <clinicalTrials>
                    <clinicalTrial>
                        <trialId>NCT02716116</trialId>
                        <title>A Trial of AP32788 in Non-Small Cell Lung Cancer</title>
                        <phase>Phase 1/Phase 2</phase>
                        <contact>Overall contact: Shuanglian Li, MD, PhD, Shuanglian.Li@ariad.com, +1 (617) 503-7148</contact>
                        <sites>
                            <site>
                                <center>Vanderbilt - Ingram Cancer Center</center>
                                <contact>Leora Horn, MD</contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Nashville</city>
                                    <state>Tennessee</state>
                                    <country>United States</country>
                                    <postalCode>37232</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Stanford Cancer Center</center>
                                <contact>Joel W Neal, MD, PhD</contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Stanford</city>
                                    <state>California</state>
                                    <country>United States</country>
                                    <postalCode>94305</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Dana Farber Cancer Institute - Site 008</center>
                                <contact>Pasi Janne, MD</contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Boston</city>
                                    <state>Massachusetts</state>
                                    <country>United States</country>
                                    <postalCode>02215</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Virginia Cancer Specialists, PC - Site 238</center>
                                <contact>Alexander Spira, MD</contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Fairfax</city>
                                    <state>Virginia</state>
                                    <country>United States</country>
                                    <postalCode>22031</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Massachusetts General Hospital Cancer Center</center>
                                <contact>Zofia Piotrowska, MD</contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Boston</city>
                                    <state>Massachusetts</state>
                                    <country>United States</country>
                                    <postalCode>02114</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Memorial Sloan Kettering Cancer Center - Site 078</center>
                                <contact>Gregory Riely, MD, PhD</contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>New York</city>
                                    <state>New York</state>
                                    <country>United States</country>
                                    <postalCode>10065</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>University of Colorado Cancer Center - Site 015</center>
                                <contact>Robert Doebele, MD</contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Aurora</city>
                                    <state>Colorado</state>
                                    <country>United States</country>
                                    <postalCode>80045</postalCode>
                                </address>
                            </site>
                        </sites>
                    </clinicalTrial>
                    <clinicalTrial>
                        <trialId>NCT02917993</trialId>
                        <title>An Open-Label Phase 1/2 Study of INCB039110 in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer</title>
                        <phase>Phase 1/Phase 2</phase>
                        <contact>Overall contact: Incyte Corporation Call Center, 1.855.463.3463</contact>
                        <sites>
                            <site>
                                <center></center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Salt Lake City</city>
                                    <state>Utah</state>
                                    <country>United States</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center></center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Whittier</city>
                                    <state>California</state>
                                    <country>United States</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center></center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Not yet recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Detroit</city>
                                    <state>Michigan</state>
                                    <country>United States</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center></center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Austin</city>
                                    <state>Texas</state>
                                    <country>United States</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center></center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Portland</city>
                                    <state>Oregon</state>
                                    <country>United States</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center></center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Lone Tree</city>
                                    <state>Colorado</state>
                                    <country>United States</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center></center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Bethlehem</city>
                                    <state>Pennsylvania</state>
                                    <country>United States</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center></center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>San Antonio</city>
                                    <state>Texas</state>
                                    <country>United States</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center></center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Fairfax</city>
                                    <state>Virginia</state>
                                    <country>United States</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center></center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Washington, D.C.</city>
                                    <state>District of Columbia</state>
                                    <country>United States</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center></center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Not yet recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Tyler</city>
                                    <state>Texas</state>
                                    <country>United States</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center></center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Boca Raton</city>
                                    <state>Florida</state>
                                    <country>United States</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                        </sites>
                    </clinicalTrial>
                    <clinicalTrial>
                        <trialId>NCT02803203</trialId>
                        <title>Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers</title>
                        <phase>Phase 1/Phase 2</phase>
                        <contact>Overall contact: Helena Yu, MD, 646 888 4274.</contact>
                        <sites>
                            <site>
                                <center>Memorial Sloan Kettering Westchester</center>
                                <contact>Helena Yu, MD</contact>
                                <investigator>Helena Yu, MD</investigator>
                                <status>Recruiting</status>
                                <prioritization>clinically</prioritization>
                                <address>
                                    <city>West Harrison</city>
                                    <state>New York</state>
                                    <country>United States</country>
                                    <postalCode>10604</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Memorial Sloan Kettering Monmouth</center>
                                <contact>Helena Yu, MD</contact>
                                <investigator>Helena Yu, MD</investigator>
                                <status>Recruiting</status>
                                <prioritization>clinically</prioritization>
                                <address>
                                    <city>Middletown</city>
                                    <state>New Jersey</state>
                                    <country>United States</country>
                                    <postalCode>07748</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Memorial Sloan Kettering at Mercy Medical Center</center>
                                <contact>Helena Yu, MD</contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>clinically</prioritization>
                                <address>
                                    <city>Rockville Centre</city>
                                    <state>New York</state>
                                    <country>United States</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Memoral Sloan Kettering Cancer Center</center>
                                <contact>Helena Yu, MD</contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>clinically</prioritization>
                                <address>
                                    <city>Basking Ridge</city>
                                    <state>New Jersey</state>
                                    <country>United States</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Memorial Sloan Kettering Cancer Center @ Suffolk</center>
                                <contact>Helena Yu, MD</contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>clinically</prioritization>
                                <address>
                                    <city>Commack</city>
                                    <state>New York</state>
                                    <country>United States</country>
                                    <postalCode>11725</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Memorial Sloan Kettering Cancer Center</center>
                                <contact>Helena Yu, MD</contact>
                                <investigator>Helena Yu, MD</investigator>
                                <status>Recruiting</status>
                                <prioritization>clinically</prioritization>
                                <address>
                                    <city>New York</city>
                                    <state>New York</state>
                                    <country>United States</country>
                                    <postalCode>10065</postalCode>
                                </address>
                            </site>
                        </sites>
                    </clinicalTrial>
                    <clinicalTrial>
                        <trialId>NCT03082300</trialId>
                        <title>A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations</title>
                        <phase>Phase 1</phase>
                        <contact>Overall contact: Astellas Pharma Global Development, astellas.registration@astellas.com, 800-888-7704 x5473</contact>
                        <sites>
                            <site>
                                <center>Beverly Hills Cancer Center</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Beverly Hills</city>
                                    <state>California</state>
                                    <country>United States</country>
                                    <postalCode>90211</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Renovatio Clinical</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>The Woodlands</city>
                                    <state>Texas</state>
                                    <country>United States</country>
                                    <postalCode>77380</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>US Oncology - Virginia Cancer Specialists, P.C. (VCS)</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Fairfax</city>
                                    <state>Virginia</state>
                                    <country>United States</country>
                                    <postalCode>22031</postalCode>
                                </address>
                            </site>
                        </sites>
                    </clinicalTrial>
                    <clinicalTrial>
                        <trialId>NCT02520778</trialId>
                        <title>Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer</title>
                        <phase>Phase 1</phase>
                        <contact></contact>
                        <sites>
                            <site>
                                <center>Duke University Medical Center</center>
                                <contact>Herbert I. Hurwitz</contact>
                                <investigator>Herbert I. Hurwitz</investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Durham</city>
                                    <state>North Carolina</state>
                                    <country>United States</country>
                                    <postalCode>27710</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Massachusetts General Hospital Cancer Center</center>
                                <contact>Geoffrey R. Oxnard</contact>
                                <investigator>Geoffrey R. Oxnard</investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Boston</city>
                                    <state>Massachusetts</state>
                                    <country>United States</country>
                                    <postalCode>02114</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>University of Colorado Cancer Center - Anschutz Cancer Pavilion</center>
                                <contact>David R. Camidge</contact>
                                <investigator>David R. Camidge</investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Aurora</city>
                                    <state>Colorado</state>
                                    <country>United States</country>
                                    <postalCode>80045</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Dana-Farber Cancer Institute</center>
                                <contact>Geoffrey R. Oxnard</contact>
                                <investigator>Geoffrey R. Oxnard</investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Boston</city>
                                    <state>Massachusetts</state>
                                    <country>United States</country>
                                    <postalCode>02215</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>University of Virginia Cancer Center</center>
                                <contact>Ryan D. Gentzler</contact>
                                <investigator>Ryan D. Gentzler</investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Charlottesville</city>
                                    <state>Virginia</state>
                                    <country>United States</country>
                                    <postalCode>22908</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>University of Kentucky/Markey Cancer Center</center>
                                <contact>Susanne M. Arnold</contact>
                                <investigator>Susanne M. Arnold</investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Lexington</city>
                                    <state>Kentucky</state>
                                    <country>United States</country>
                                    <postalCode>40536</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Rutgers Cancer Institute of New Jersey</center>
                                <contact>Jyoti Malhotra</contact>
                                <investigator>Jyoti Malhotra</investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>New Brunswick</city>
                                    <state>New Jersey</state>
                                    <country>United States</country>
                                    <postalCode>08903</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital</center>
                                <contact>Jyoti Malhotra</contact>
                                <investigator>Jyoti Malhotra</investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>New Brunswick</city>
                                    <state>New Jersey</state>
                                    <country>United States</country>
                                    <postalCode>08903</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Ohio State University Comprehensive Cancer Center</center>
                                <contact>Erin M. Bertino</contact>
                                <investigator>Erin M. Bertino</investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Columbus</city>
                                    <state>Ohio</state>
                                    <country>United States</country>
                                    <postalCode>43210</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Johns Hopkins University/Sidney Kimmel Cancer Center</center>
                                <contact>Christine L. Hann</contact>
                                <investigator>Christine L. Hann</investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Baltimore</city>
                                    <state>Maryland</state>
                                    <country>United States</country>
                                    <postalCode>21287</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>UNC Lineberger Comprehensive Cancer Center</center>
                                <contact>Jared M. Weiss</contact>
                                <investigator>Jared M. Weiss</investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Chapel Hill</city>
                                    <state>North Carolina</state>
                                    <country>United States</country>
                                    <postalCode>27599</postalCode>
                                </address>
                            </site>
                        </sites>
                    </clinicalTrial>
                    <clinicalTrial>
                        <trialId>NCT02759835</trialId>
                        <title>Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib</title>
                        <phase>Phase 2</phase>
                        <contact>Overall contact: Susan A Perry, R.N., perrys@mail.nih.gov, (301) 402-4423</contact>
                        <sites>
                            <site>
                                <center>National Institutes of Health Clinical Center</center>
                                <contact>For more information at the NIH Clinical Center contact National Cancer Institute Referral Office</contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>clinically</prioritization>
                                <address>
                                    <city>Bethesda</city>
                                    <state>Maryland</state>
                                    <country>United States</country>
                                    <postalCode>20892</postalCode>
                                </address>
                            </site>
                        </sites>
                    </clinicalTrial>
                    <clinicalTrial>
                        <trialId>NCT02511106</trialId>
                        <title>AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.</title>
                        <phase>Phase 3</phase>
                        <contact>Overall contact: AstraZeneca Clinical Study Information Center, information.center@astrazeneca.com, 1-877-240-9479</contact>
                        <sites>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Los Angeles</city>
                                    <state>California</state>
                                    <country>United States</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Las Palmas de Gran Canaria</city>
                                    <state></state>
                                    <country>Spain</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Dnipropetrovsk</city>
                                    <state></state>
                                    <country>Ukraine</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Haifa</city>
                                    <state></state>
                                    <country>Israel</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Hanoi</city>
                                    <state></state>
                                    <country>Vietnam</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Halle</city>
                                    <state></state>
                                    <country>Germany</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Not yet recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Fukuoka</city>
                                    <state></state>
                                    <country>Japan</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Valencia</city>
                                    <state></state>
                                    <country>Spain</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Immenhausen</city>
                                    <state></state>
                                    <country>Germany</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Bricktown</city>
                                    <state>New Jersey</state>
                                    <country>United States</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Bergamo</city>
                                    <state></state>
                                    <country>Italy</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Saint-Petersburg</city>
                                    <state></state>
                                    <country>Russian Federation</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Madrid</city>
                                    <state></state>
                                    <country>Spain</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Kanazawa</city>
                                    <state></state>
                                    <country>Japan</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Not yet recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Suwon</city>
                                    <state></state>
                                    <country>Korea, Republic of</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Saint Petersburg</city>
                                    <state></state>
                                    <country>Russian Federation</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Roma</city>
                                    <state></state>
                                    <country>Italy</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Xi'an</city>
                                    <state></state>
                                    <country>China</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Sakai-shi</city>
                                    <state></state>
                                    <country>Japan</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Kazan</city>
                                    <state></state>
                                    <country>Russian Federation</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Shinjuku-ku</city>
                                    <state></state>
                                    <country>Japan</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Not yet recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Tianjin</city>
                                    <state></state>
                                    <country>China</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Urumchi</city>
                                    <state></state>
                                    <country>China</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Not yet recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Kharkiv</city>
                                    <state></state>
                                    <country>Ukraine</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Bakersfield</city>
                                    <state>California</state>
                                    <country>United States</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Linköping</city>
                                    <state></state>
                                    <country>Sweden</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Brussels</city>
                                    <state></state>
                                    <country>Belgium</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Hollywood</city>
                                    <state>Florida</state>
                                    <country>United States</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Uzhgorod</city>
                                    <state></state>
                                    <country>Ukraine</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Urumqi</city>
                                    <state></state>
                                    <country>China</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Khonkaen</city>
                                    <state></state>
                                    <country>Thailand</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Yokohama-shi</city>
                                    <state></state>
                                    <country>Japan</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Tainan</city>
                                    <state></state>
                                    <country>Taiwan</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Osakasayama-shi</city>
                                    <state></state>
                                    <country>Japan</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Gent</city>
                                    <state></state>
                                    <country>Belgium</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Darlinghurst</city>
                                    <state></state>
                                    <country>Australia</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Kobe-shi</city>
                                    <state></state>
                                    <country>Japan</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Tel Hashomer</city>
                                    <state></state>
                                    <country>Israel</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Fortaleza</city>
                                    <state></state>
                                    <country>Brazil</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Taipei</city>
                                    <state></state>
                                    <country>Taiwan</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Coswig</city>
                                    <state></state>
                                    <country>Germany</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Not yet recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Shanghai</city>
                                    <state></state>
                                    <country>China</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Zaporizhzhya</city>
                                    <state></state>
                                    <country>Ukraine</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Kassel</city>
                                    <state></state>
                                    <country>Germany</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Fort Myers</city>
                                    <state>Florida</state>
                                    <country>United States</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Pyatigorsk</city>
                                    <state></state>
                                    <country>Russian Federation</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Parma</city>
                                    <state></state>
                                    <country>Italy</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Changhua</city>
                                    <state></state>
                                    <country>Taiwan</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Padova</city>
                                    <state></state>
                                    <country>Italy</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Bursa</city>
                                    <state></state>
                                    <country>Turkey</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Heidelberg</city>
                                    <state></state>
                                    <country>Australia</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Beijing</city>
                                    <state></state>
                                    <country>China</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Woolloongabba</city>
                                    <state></state>
                                    <country>Australia</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Ankara</city>
                                    <state></state>
                                    <country>Turkey</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Kitakyushu-shi</city>
                                    <state></state>
                                    <country>Japan</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Not yet recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Guangzhou</city>
                                    <state></state>
                                    <country>China</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Saint Petersburg</city>
                                    <state>Florida</state>
                                    <country>United States</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Salvador</city>
                                    <state></state>
                                    <country>Brazil</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Cheongju-si</city>
                                    <state></state>
                                    <country>Korea, Republic of</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Liou Ying Township</city>
                                    <state></state>
                                    <country>Taiwan</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Redondo Beach</city>
                                    <state>California</state>
                                    <country>United States</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Nagoya-shi</city>
                                    <state></state>
                                    <country>Japan</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Suzhou</city>
                                    <state></state>
                                    <country>China</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Bari</city>
                                    <state></state>
                                    <country>Italy</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Lugo</city>
                                    <state></state>
                                    <country>Spain</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Elk Grove Village</city>
                                    <state>Illinois</state>
                                    <country>United States</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Not yet recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Kursk</city>
                                    <state></state>
                                    <country>Russian Federation</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Barcelona</city>
                                    <state></state>
                                    <country>Spain</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Majadahonda</city>
                                    <state></state>
                                    <country>Spain</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>New Haven</city>
                                    <state>Connecticut</state>
                                    <country>United States</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Tel Aviv</city>
                                    <state></state>
                                    <country>Israel</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Chicago</city>
                                    <state>Illinois</state>
                                    <country>United States</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Málaga</city>
                                    <state></state>
                                    <country>Spain</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Cachoeira De Itapemirim</city>
                                    <state></state>
                                    <country>Brazil</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Sunto-gun</city>
                                    <state></state>
                                    <country>Japan</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Großhansdorf</city>
                                    <state></state>
                                    <country>Germany</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Chom Thon</city>
                                    <state></state>
                                    <country>Thailand</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Phitsanulok</city>
                                    <state></state>
                                    <country>Thailand</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Berlin</city>
                                    <state></state>
                                    <country>Germany</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Not yet recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Kunming</city>
                                    <state></state>
                                    <country>China</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Santa Monica</city>
                                    <state>California</state>
                                    <country>United States</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Not yet recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Izmir</city>
                                    <state></state>
                                    <country>Turkey</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Frankston</city>
                                    <state></state>
                                    <country>Australia</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Seoul</city>
                                    <state></state>
                                    <country>Korea, Republic of</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>A Coruña</city>
                                    <state></state>
                                    <country>Spain</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Paris</city>
                                    <state></state>
                                    <country>France</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Bucharest</city>
                                    <state></state>
                                    <country>Romania</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Norwalk</city>
                                    <state>Connecticut</state>
                                    <country>United States</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Yonago-shi</city>
                                    <state></state>
                                    <country>Japan</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Chiayi</city>
                                    <state></state>
                                    <country>Taiwan</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Meldola</city>
                                    <state></state>
                                    <country>Italy</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Taichung</city>
                                    <state></state>
                                    <country>Taiwan</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Palermo</city>
                                    <state></state>
                                    <country>Italy</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Bethesda</city>
                                    <state>Maryland</state>
                                    <country>United States</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Craiova</city>
                                    <state></state>
                                    <country>Romania</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Gauting</city>
                                    <state></state>
                                    <country>Germany</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Bangkok</city>
                                    <state></state>
                                    <country>Thailand</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Nashville</city>
                                    <state>Tennessee</state>
                                    <country>United States</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Barretos</city>
                                    <state></state>
                                    <country>Brazil</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Bron</city>
                                    <state></state>
                                    <country>France</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Nanning</city>
                                    <state></state>
                                    <country>China</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Sasebo-shi</city>
                                    <state></state>
                                    <country>Japan</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Budapest</city>
                                    <state></state>
                                    <country>Hungary</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Zaragoza</city>
                                    <state></state>
                                    <country>Spain</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Itajai</city>
                                    <state></state>
                                    <country>Brazil</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Hirakata-shi</city>
                                    <state></state>
                                    <country>Japan</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Kogarah</city>
                                    <state></state>
                                    <country>Australia</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Bruxelles</city>
                                    <state></state>
                                    <country>Belgium</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Honolulu</city>
                                    <state>Hawaii</state>
                                    <country>United States</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Brussels (Anderlecht)</city>
                                    <state></state>
                                    <country>Belgium</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>St. Petersburg</city>
                                    <state></state>
                                    <country>Russian Federation</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Sumy</city>
                                    <state></state>
                                    <country>Ukraine</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Pawtucket</city>
                                    <state>Rhode Island</state>
                                    <country>United States</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Camperdown</city>
                                    <state></state>
                                    <country>Australia</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Homburg</city>
                                    <state></state>
                                    <country>Germany</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Petah Tikva</city>
                                    <state></state>
                                    <country>Israel</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Florianópolis</city>
                                    <state></state>
                                    <country>Brazil</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Milano</city>
                                    <state></state>
                                    <country>Italy</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Hiroshima-shi</city>
                                    <state></state>
                                    <country>Japan</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Otwock</city>
                                    <state></state>
                                    <country>Poland</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Not yet recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Rostov-on-Don</city>
                                    <state></state>
                                    <country>Russian Federation</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Ottignies</city>
                                    <state></state>
                                    <country>Belgium</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Not yet recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Shenyang</city>
                                    <state></state>
                                    <country>China</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Fort Belvoir</city>
                                    <state>Virginia</state>
                                    <country>United States</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Bunkyo-ku</city>
                                    <state></state>
                                    <country>Japan</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Eindhoven</city>
                                    <state></state>
                                    <country>Netherlands</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Oslo</city>
                                    <state></state>
                                    <country>Norway</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Arkhangelsk</city>
                                    <state></state>
                                    <country>Russian Federation</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Ryazan</city>
                                    <state></state>
                                    <country>Russian Federation</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Rio Grande do Sul</city>
                                    <state></state>
                                    <country>Brazil</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Trier</city>
                                    <state></state>
                                    <country>Germany</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Lübeck</city>
                                    <state></state>
                                    <country>Germany</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Kfar Saba</city>
                                    <state></state>
                                    <country>Israel</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Not yet recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Würzburg</city>
                                    <state></state>
                                    <country>Germany</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Iasi</city>
                                    <state></state>
                                    <country>Romania</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>São José do Rio Preto</city>
                                    <state></state>
                                    <country>Brazil</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Changchun</city>
                                    <state></state>
                                    <country>China</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Sendai-shi</city>
                                    <state></state>
                                    <country>Japan</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Livorno</city>
                                    <state></state>
                                    <country>Italy</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>San Sebastian</city>
                                    <state></state>
                                    <country>Spain</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Racibórz</city>
                                    <state></state>
                                    <country>Poland</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Yangzhou</city>
                                    <state></state>
                                    <country>China</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Gerlingen</city>
                                    <state></state>
                                    <country>Germany</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Istanbul</city>
                                    <state></state>
                                    <country>Turkey</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Baudour</city>
                                    <state></state>
                                    <country>Belgium</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Spokane</city>
                                    <state>Washington</state>
                                    <country>United States</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Hochiminh</city>
                                    <state></state>
                                    <country>Vietnam</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Łódź</city>
                                    <state></state>
                                    <country>Poland</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Timisoara</city>
                                    <state></state>
                                    <country>Romania</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Songkla</city>
                                    <state></state>
                                    <country>Thailand</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Curitiba</city>
                                    <state></state>
                                    <country>Brazil</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Beer-Sheva</city>
                                    <state></state>
                                    <country>Israel</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Ube-shi</city>
                                    <state></state>
                                    <country>Japan</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Ho Chi Minh</city>
                                    <state></state>
                                    <country>Vietnam</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Hong Kong</city>
                                    <state></state>
                                    <country>Hong Kong</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Not yet recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Istanbul</city>
                                    <state></state>
                                    <country>Turkey</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Sagamihara-shi</city>
                                    <state></state>
                                    <country>Japan</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Suwon-si</city>
                                    <state></state>
                                    <country>Korea, Republic of</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Aachen</city>
                                    <state></state>
                                    <country>Germany</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Santa Rosa</city>
                                    <state>California</state>
                                    <country>United States</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Hangzhou</city>
                                    <state></state>
                                    <country>China</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Athens</city>
                                    <state>Georgia</state>
                                    <country>United States</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Not yet recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Matsuyama-shi</city>
                                    <state></state>
                                    <country>Japan</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Izmir</city>
                                    <state></state>
                                    <country>Turkey</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Bedford Park</city>
                                    <state></state>
                                    <country>Australia</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Hoofddorp</city>
                                    <state></state>
                                    <country>Netherlands</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Vinnytsia</city>
                                    <state></state>
                                    <country>Ukraine</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Limoges</city>
                                    <state></state>
                                    <country>France</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Shanghai</city>
                                    <state></state>
                                    <country>China</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Lille cedex</city>
                                    <state></state>
                                    <country>France</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Poznan</city>
                                    <state></state>
                                    <country>Poland</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Sankt-Peterburg</city>
                                    <state></state>
                                    <country>Russian Federation</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Lviv</city>
                                    <state></state>
                                    <country>Ukraine</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Cremona</city>
                                    <state></state>
                                    <country>Italy</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>São Paulo</city>
                                    <state></state>
                                    <country>Brazil</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Bologna</city>
                                    <state></state>
                                    <country>Italy</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Elche</city>
                                    <state></state>
                                    <country>Spain</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Not yet recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Seoul</city>
                                    <state></state>
                                    <country>Korea, Republic of</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Guangzhou</city>
                                    <state></state>
                                    <country>China</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Tianjin</city>
                                    <state></state>
                                    <country>China</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Moscow</city>
                                    <state></state>
                                    <country>Russian Federation</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Bucuresti</city>
                                    <state></state>
                                    <country>Romania</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Not yet recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Zhengzhou</city>
                                    <state></state>
                                    <country>China</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Muang</city>
                                    <state></state>
                                    <country>Thailand</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Grand Junction</city>
                                    <state>Colorado</state>
                                    <country>United States</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Kashiwa-shi</city>
                                    <state></state>
                                    <country>Japan</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Nanjing</city>
                                    <state></state>
                                    <country>China</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Matsuyama-shi</city>
                                    <state></state>
                                    <country>Japan</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Lyon</city>
                                    <state></state>
                                    <country>France</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Xiamen</city>
                                    <state></state>
                                    <country>China</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Novara</city>
                                    <state></state>
                                    <country>Italy</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Székesfehérvár</city>
                                    <state></state>
                                    <country>Hungary</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Not yet recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Moscow</city>
                                    <state></state>
                                    <country>Russian Federation</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Arnhem</city>
                                    <state></state>
                                    <country>Netherlands</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Porto Alegre</city>
                                    <state></state>
                                    <country>Brazil</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Lucca</city>
                                    <state></state>
                                    <country>Italy</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Not yet recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Obninsk</city>
                                    <state></state>
                                    <country>Russian Federation</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Chattanooga</city>
                                    <state>Tennessee</state>
                                    <country>United States</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Kurralta Park</city>
                                    <state></state>
                                    <country>Australia</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Focsani</city>
                                    <state></state>
                                    <country>Romania</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Zwolle</city>
                                    <state></state>
                                    <country>Netherlands</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Köln</city>
                                    <state></state>
                                    <country>Germany</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Dalian</city>
                                    <state></state>
                                    <country>China</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Torokbalint</city>
                                    <state></state>
                                    <country>Hungary</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Kortrijk</city>
                                    <state></state>
                                    <country>Belgium</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Not yet recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Orbassano</city>
                                    <state></state>
                                    <country>Italy</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                        </sites>
                    </clinicalTrial>
                    <clinicalTrial>
                        <trialId>NCT02108964</trialId>
                        <title>A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies</title>
                        <phase>Phase 1/Phase 2</phase>
                        <contact>Overall contact: Novartis Pharmaceuticals, novartis.email@novartis.com, 1-888-669-6682</contact>
                        <sites>
                            <site>
                                <center>Novartis Investigative Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>clinically</prioritization>
                                <address>
                                    <city>Seoul</city>
                                    <state>Korea</state>
                                    <country>Korea, Republic of</country>
                                    <postalCode>05505</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Novartis Investigative Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>clinically</prioritization>
                                <address>
                                    <city>Barcelona</city>
                                    <state>Catalunya</state>
                                    <country>Spain</country>
                                    <postalCode>08035</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Novartis Investigative Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>clinically</prioritization>
                                <address>
                                    <city>Seoul</city>
                                    <state>Korea</state>
                                    <country>Korea, Republic of</country>
                                    <postalCode>03080</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Novartis Investigative Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>clinically</prioritization>
                                <address>
                                    <city>Milano</city>
                                    <state>MI</state>
                                    <country>Italy</country>
                                    <postalCode>20133</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Novartis Investigative Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>clinically</prioritization>
                                <address>
                                    <city>Toronto</city>
                                    <state>Ontario</state>
                                    <country>Canada</country>
                                    <postalCode>M5G 2M9</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Novartis Investigative Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>clinically</prioritization>
                                <address>
                                    <city>Koeln</city>
                                    <state>Nordrhein-Westfalen</state>
                                    <country>Germany</country>
                                    <postalCode>50937</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Novartis Investigative Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>clinically</prioritization>
                                <address>
                                    <city>Singapore</city>
                                    <state></state>
                                    <country>Singapore</country>
                                    <postalCode>169610</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Novartis Investigative Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>clinically</prioritization>
                                <address>
                                    <city>Madrid</city>
                                    <state></state>
                                    <country>Spain</country>
                                    <postalCode>28041</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Novartis Investigative Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>clinically</prioritization>
                                <address>
                                    <city>Amsterdam</city>
                                    <state></state>
                                    <country>Netherlands</country>
                                    <postalCode>1066</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Memorial Sloan Kettering Cancer Center Oncology Department</center>
                                <contact>Murielle Georges</contact>
                                <investigator>Gregory J. Riely</investigator>
                                <status>Recruiting</status>
                                <prioritization>clinically</prioritization>
                                <address>
                                    <city>New York</city>
                                    <state>New York</state>
                                    <country>United States</country>
                                    <postalCode>10065</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Massachusetts General Hospital Mass General</center>
                                <contact>Elizabeth E. Kennedy</contact>
                                <investigator>Lecia Sequist</investigator>
                                <status>Recruiting</status>
                                <prioritization>clinically</prioritization>
                                <address>
                                    <city>Boston</city>
                                    <state>Massachusetts</state>
                                    <country>United States</country>
                                    <postalCode>02114</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Novartis Investigative Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>clinically</prioritization>
                                <address>
                                    <city>Fukuoka</city>
                                    <state></state>
                                    <country>Japan</country>
                                    <postalCode>811-1395</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Novartis Investigative Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>clinically</prioritization>
                                <address>
                                    <city>Taipei</city>
                                    <state>Taiwan ROC</state>
                                    <country>Taiwan</country>
                                    <postalCode>10041</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Novartis Investigative Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>clinically</prioritization>
                                <address>
                                    <city>Nagoya</city>
                                    <state>Aichi</state>
                                    <country>Japan</country>
                                    <postalCode>464-8681</postalCode>
                                </address>
                            </site>
                        </sites>
                    </clinicalTrial>
                    <clinicalTrial>
                        <trialId>NCT02674555</trialId>
                        <title>A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors</title>
                        <phase>Phase 1</phase>
                        <contact>Overall contact: Clinical Pharmacology and Exploratory Development, astellas.registration@astellas.com, +31 (0) 71 5455 500</contact>
                        <sites>
                            <site>
                                <center>Site US10001</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>clinically</prioritization>
                                <address>
                                    <city>Cleveland</city>
                                    <state>Ohio</state>
                                    <country>United States</country>
                                    <postalCode>44195</postalCode>
                                </address>
                            </site>
                        </sites>
                    </clinicalTrial>
                </clinicalTrials>
            </treatment>
        </alteration>
        <alteration>
            <type>indel</type>
            <gene>EGFR</gene>
            <name>E746_A750del</name>
            <description>Exon 19 Deletion</description>
            <method>deletion</method>
            <detected>true</detected>
            <value>12.7%</value>
            <indel>
                <cfdnaPercentage>12.7</cfdnaPercentage>
                <exon>19</exon>
                <cdna>c.2235_2249delGGAATTAAGAGAAGC</cdna>
                <chromosome>7</chromosome>
                <aminoAcidMutation>E746_A750del</aminoAcidMutation>
                <nucleotideMutation>AGGAATTAAGAGAAGC>A</nucleotideMutation>
                <position>55242464</position>
                <length>15</length>
                <transcriptId>NM_005228.3</transcriptId>
                <reportingCategory>protein_coding</reportingCategory>
            </indel>
            <treatment>
                <trialAvailable>true</trialAvailable>
                <therapies>
                    <therapy>
                        <drug>Pyrotinib</drug>
                        <tradeName></tradeName>
                        <rationale>Egfr/Her2 kinase inhibitor.</rationale>
                        <disease>Non-small cell lung carcinoma (NSCLC)</disease>
                        <status>Phase 2</status>
                        <otherDiseases>---
- Breast carcinoma
</otherDiseases>
                        <otherStatus>Phase 3</otherStatus>
                    </therapy>
                    <therapy>
                        <drug>EGF816</drug>
                        <tradeName></tradeName>
                        <rationale>Third generation EGFR mutant-selective (T790M, L858R, exon 19 deletion) tyrosine kinase inhibitor.</rationale>
                        <disease>Non-small cell lung carcinoma (NSCLC)</disease>
                        <status>Phase 2</status>
                        <otherStatus></otherStatus>
                    </therapy>
                    <therapy>
                        <drug>TH4000</drug>
                        <tradeName></tradeName>
                        <rationale>Hypoxia-activated Egfr tyrosine kinase inhibitor.</rationale>
                        <disease>Non-small cell lung carcinoma (NSCLC)</disease>
                        <status>Phase 2</status>
                        <otherDiseases>---
- Head and neck squamous cell carcinoma (HNSCC)
</otherDiseases>
                        <otherStatus>Phase 2</otherStatus>
                    </therapy>
                    <therapy>
                        <drug>Dacomitinib</drug>
                        <tradeName></tradeName>
                        <rationale>Pan-ErbB family tyrosine kinase inhibitor.</rationale>
                        <disease>Non-small cell lung carcinoma (NSCLC)</disease>
                        <status>Phase 3</status>
                        <otherDiseases>---
- Gastric carcinoma
- Glioblastoma
- Glioma
- Pancreatic carcinoma
- Head and neck carcinoma
- Cutaneous squamous cell carcinoma
- Esophageal carcinoma
- Penile carcinoma
- Colorectal carcinoma (CRC)
</otherDiseases>
                        <otherStatus>Phase 2</otherStatus>
                    </therapy>
                    <therapy>
                        <drug>Neratinib</drug>
                        <tradeName></tradeName>
                        <rationale>Egfr/Her2/ErbB4 inhibitor.</rationale>
                        <disease>Non-small cell lung carcinoma (NSCLC)</disease>
                        <status>Phase 2</status>
                        <otherDiseases>---
- Breast carcinoma
</otherDiseases>
                        <otherStatus>Phase 3</otherStatus>
                    </therapy>
                    <therapy>
                        <drug>AP32788</drug>
                        <tradeName></tradeName>
                        <rationale>Egfr/Her2 mutant-selective inhibitor.</rationale>
                        <disease>Non-small cell lung carcinoma (NSCLC)</disease>
                        <status>Phase 2</status>
                        <otherStatus></otherStatus>
                    </therapy>
                    <therapy>
                        <drug>Varlitinib</drug>
                        <tradeName></tradeName>
                        <rationale>Egfr/Her2 inhibitor.</rationale>
                        <disease></disease>
                        <status></status>
                        <otherDiseases>---
- Gastric carcinoma
- Pancreatic carcinoma
</otherDiseases>
                        <otherStatus>Phase 2</otherStatus>
                    </therapy>
                    <therapy>
                        <drug>Icotinib</drug>
                        <tradeName>Conmana</tradeName>
                        <rationale>Egfr inhibitor.</rationale>
                        <disease>Non-small cell lung carcinoma (NSCLC)</disease>
                        <status>Phase 3</status>
                        <otherDiseases>---
- Esophageal carcinoma
</otherDiseases>
                        <otherStatus>Phase 2</otherStatus>
                    </therapy>
                    <therapy>
                        <drug>KBP-5209</drug>
                        <tradeName></tradeName>
                        <rationale>ErbB family inhibitor.</rationale>
                        <disease>Solid Tumor</disease>
                        <status>Phase 1</status>
                        <otherStatus></otherStatus>
                    </therapy>
                    <therapy>
                        <drug>ASP8273</drug>
                        <tradeName></tradeName>
                        <rationale>EGFR mutant-specific inhibitor.</rationale>
                        <disease>Non-small cell lung carcinoma (NSCLC)</disease>
                        <status>Phase 3</status>
                        <otherDiseases>---
- Solid Tumor
</otherDiseases>
                        <otherStatus>Phase 1</otherStatus>
                    </therapy>
                </therapies>
                <clinicalRelevances>
                    <clinicalRelevance>
                        <roleInDisease>The presence of an EGFR abnormality (mutation, amplification, or overexpression) can result in an overabundance or overactivity of Egfr protein, which can lead to excessive proliferation (Ciardiello and Tortora, 2008; 18337605). EGFR mutations in NSCLC have been reported to occur more frequently in women, never-smokers, and in patients with adenocarcinoma histology (Rizzo et al., 2016; 25956936, Lee et al., 2015; 26359571, Naderi et al., 2015; 26362141, Zhou et al., 2016; 27039821, Lee et al., 2016; 26992209, Zhang et al., 2016; 27738317).</roleInDisease>
                        <drugSensitivity>The presence of a sensitizing EGFR mutation in a tumor is the strongest biological predictor of sensitivity to an Egfr tyrosine kinase inhibitor (TKI). Compared with conventional chemotherapy, Egfr TKIs have been shown to improve progression-free survival in non-small cell lung cancer patients whose tumors harbor EGFR mutations (Mok et al., 2009; 19692680, Rosell et al., 2009; 19692684, Tsao et al., 2005; 16014883, Rosell et al., 2012; 22285168). The Egfr TKIs erlotinib, afatinib, and gefitinib have been approved by the FDA for the treatment of EGFR mutant non-small cell lung cancer (NSCLC) (Shepherd et al., 2005; 16014882, Rosell et al., 2012; 22285168, Sequist et al., 2013; 23816960, Douillard et al., 2014; 24263064, Mok et al., 2009; 19692680). Erlotinib, in combination with gemcitabine, has also been approved by the FDA for the treatment of locally advanced, unresectable, or metastatic pancreatic cancer (Moore et al., 2007; 17452677, Senderowicz et al., 2007; 18247017). For NSCLC patients with metastatic disease and tumors harboring a sensitizing EGFR mutation, the NCCN guidelines (v.2.2016) suggest treating with erlotinib, afatinib, or gefitinib if the alteration is discovered prior to first-line chemotherapy or interrupting/completing current therapy and treating with erlotinib, afatinib, or gefitinib if the alteration is discovered during first-line chemotherapy. However, EGFR T790M, also detected in this tumor, has been associated with resistance to the Egfr tyrosine kinase inhibitors erlotinib, gefitinib, and afatinib (Greulich et al., 2005; 16187797, Suda et al., 2009; 19096299, Denis et al., 2015; 25668228, Wu et al., 2016; 26862733, Yang et al., 2015; 26051236, Kim et al., 2012; 22228822).</drugSensitivity>
                        <drugResistance>Some patients with EGFR-mutant NSCLC exhibit resistance to Egfr inhibition; resistance has been associated with insertions in EGFR exon 20, the T790M mutation in EGFR, and amplification of the gene MET (Engelman et al., 2007; 17463250, Greulich et al., 2005; 16187797, Kwak et al., 2005; 15897464). Third generation irreversible Egfr TKIs that target the EGFR T790M mutation have shown efficacy in T790M-mutant NSCLC and are under clinical investigation, including osimertinib, which has received FDA-approval for the treatment of EGFR T790M-mutant metastatic NSCLC (Jänne et al., 2011; 21220471, Jänne et al., 2015; 25923549, Greig, 2016; 26729184, Yang et al., 2016; 27198353, Wang et al., 2016; 27071706). Several studies have reported that resistance to Egfr TKIs in NSCLC is mediated by the transformation of NSCLC cell types to those of SCLC with neuroendocrine features (Watanabe et al., 2013; 24012411, Chang et al., 2013; 24101933, Popat et al., 2013; 23312887, Sequist et al., 2011; 21430269).</drugResistance>
                    </clinicalRelevance>
                </clinicalRelevances>
                <biologicalSignificances>
                    <biologicalSignificance>
                        <content>EGFR-E746_A750del is an activating mutation. EGFR activating mutations or amplification may predict sensitivity to Egfr-targeted therapies, including inhibitors of multiple ErbB family members, and several have received FDA approval in some tumor types (Mok et al., 2009; 19692680, Rosell et al., 2009; 19692684, Tsao et al., 2005; 16014883). Egfr activation or overexpression may also lead to activation of the PI3K and MAPK pathway and may confer sensitivity to PI3K and MAPK pathway inhibitors (Bancroft et al., 2002; 11992543). EGFR T790M, also detected in this tumor, has been associated with resistance to the Egfr tyrosine kinase inhibitors erlotinib, gefitinib, and afatinib (Greulich et al., 2005; 16187797, Suda et al., 2009; 19096299, Denis et al., 2015; 25668228, Wu et al., 2016; 26862733, Yang et al., 2015; 26051236, Kim et al., 2012; 22228822).</content>
                        <molecularFunction>E746_A750del is located in the kinase domain of Egfr; this mutation and other exon 19 deletions have been shown to activate the tyrosine kinase activity of Egfr and confer sensitivity to Egfr tyrosine kinase inhibitors such as erlotinib and gefitinib (Lynch et al., 2004; 15118073, Paez et al., 2004; 15118125, Pao et al., 2004; 15329413).</molecularFunction>
                        <incidence>EGFR mutations have been reported in 37% (14530/39587) of Lung adenocarcinoma samples analyzed in COSMIC (Apr 2017). EGFR mutations have been reported in 5.9-18% of Lung adenocarcinoma samples (cBioPortal for Cancer Genomics, Apr 2017). EGFR mutations have been reported in 14-49% of NSCLC cases, and found to be more common in East Asian patients as compared with other ethnicities (Vallee et al., 2013; 23934203, Rizzo et al., 2016; 25956936, Arrieta et al., 2015; 26358312, Zhou et al., 2016; 27039821, Lee et al., 2016; 26992209, Zhang et al., 2016; 27738317).</incidence>
                    </biologicalSignificance>
                </biologicalSignificances>
                <clinicalTrials>
                    <clinicalTrial>
                        <trialId>NCT02908750</trialId>
                        <title>Study to Assess the Effect of Osimertinib (TAGRISSO™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC</title>
                        <phase>Phase 1</phase>
                        <contact>Overall contact: AstraZeneca Clinical Study Information Center, information.center@astrazeneca.com, 1-877-240-9479</contact>
                        <sites>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Not yet recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Dijon cedex</city>
                                    <state></state>
                                    <country>France</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Not yet recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Bordeaux Cedex</city>
                                    <state></state>
                                    <country>France</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Madrid</city>
                                    <state></state>
                                    <country>Spain</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Not yet recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Seoul</city>
                                    <state></state>
                                    <country>Korea, Republic of</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Not yet recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Sevilla</city>
                                    <state></state>
                                    <country>Spain</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Not yet recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Rennes Cedex 9</city>
                                    <state></state>
                                    <country>France</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Not yet recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Madrid</city>
                                    <state></state>
                                    <country>Spain</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Not yet recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Saint Herblain</city>
                                    <state></state>
                                    <country>France</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Research Site</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Not yet recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Seongnam-si</city>
                                    <state></state>
                                    <country>Korea, Republic of</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                        </sites>
                    </clinicalTrial>
                    <clinicalTrial>
                        <trialId>NCT01918761</trialId>
                        <title>Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)</title>
                        <phase>Phase 1</phase>
                        <contact></contact>
                        <sites>
                            <site>
                                <center>Medizinische Universität Graz Klinische Abteilung für Onkologie</center>
                                <contact>Hellmut Samonigg, MD</contact>
                                <investigator>Hellmut Samonigg, MD</investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Graz</city>
                                    <state></state>
                                    <country>Austria</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Universitätsklinik für Innere Medizin I</center>
                                <contact>Georg Pall, MD</contact>
                                <investigator>Georg Pall, MD</investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Innsbruck</city>
                                    <state></state>
                                    <country>Austria</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                        </sites>
                    </clinicalTrial>
                    <clinicalTrial>
                        <trialId>NCT01929200</trialId>
                        <title>Icotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR Mutation</title>
                        <phase>Phase 2</phase>
                        <contact>Overall contact: Yue Yang, MD, zlyangyue@bjmu.edu.cn, 86-10-88196568</contact>
                        <sites>
                            <site>
                                <center>Beijing Cancer hospital</center>
                                <contact>Yue Yang, MD</contact>
                                <investigator>Yue Yang, MD</investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Beijing</city>
                                    <state></state>
                                    <country>China</country>
                                    <postalCode>100142</postalCode>
                                </address>
                            </site>
                        </sites>
                    </clinicalTrial>
                    <clinicalTrial>
                        <trialId>NCT02349633</trialId>
                        <title>Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)</title>
                        <phase>Phase 1/Phase 2</phase>
                        <contact>Overall contact: Pfizer CT.gov Call Center, 1-800-718-1021</contact>
                        <sites>
                            <site>
                                <center>UC San Diego Medical Center - La Jolla</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>La Jolla</city>
                                    <state>California</state>
                                    <country>United States</country>
                                    <postalCode>92307</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Severance Hospital, Yonsei University Health System</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Seoul</city>
                                    <state></state>
                                    <country>Korea, Republic of</country>
                                    <postalCode>120-752</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>UC San Diego Moores Cancer Center</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>La Jolla</city>
                                    <state>California</state>
                                    <country>United States</country>
                                    <postalCode>92093-0698</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Seattle Cancer Care Alliance</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Seattle</city>
                                    <state>Washington</state>
                                    <country>United States</country>
                                    <postalCode>98109</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>UC San Diego Moores Cancer Center - Investigational Drug Services</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>La Jolla</city>
                                    <state>California</state>
                                    <country>United States</country>
                                    <postalCode>92037-0845</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>UC San Diego Medical Center - Hillcrest</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>San Diego</city>
                                    <state>California</state>
                                    <country>United States</country>
                                    <postalCode>92103</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Hillman Cancer Center</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Pittsburgh</city>
                                    <state>Pennsylvania</state>
                                    <country>United States</country>
                                    <postalCode>15232</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>UPMC Hillman Cancer Center</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Pittsburgh</city>
                                    <state>Pennsylvania</state>
                                    <country>United States</country>
                                    <postalCode>15232</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>University of Washington Medical Center</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Seattle</city>
                                    <state>Washington</state>
                                    <country>United States</country>
                                    <postalCode>98195</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Seoul National University Hospital / Department of Internal Medicine</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Seoul</city>
                                    <state></state>
                                    <country>Korea, Republic of</country>
                                    <postalCode>110-744</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Smilow Cancer Hospital at Yale-New Haven</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>New Haven</city>
                                    <state>Connecticut</state>
                                    <country>United States</country>
                                    <postalCode>06510</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>UPMC Cancer Pavilion</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Pittsburgh</city>
                                    <state>Pennsylvania</state>
                                    <country>United States</country>
                                    <postalCode>15232</postalCode>
                                </address>
                            </site>
                        </sites>
                    </clinicalTrial>
                    <clinicalTrial>
                        <trialId>NCT02648425</trialId>
                        <title>Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin With Capecitabine</title>
                        <phase>Phase 1</phase>
                        <contact>Overall contact: ASLAN Pharma, contact@aslanpharma.com, +65 6222 4235</contact>
                        <sites>
                            <site>
                                <center>Queen Mary Hospital</center>
                                <contact>Queen Mary Hospital</contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Hong Kong</city>
                                    <state></state>
                                    <country>Hong Kong</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>National Taiwan University Hospital</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Taipei</city>
                                    <state></state>
                                    <country>Taiwan</country>
                                    <postalCode>100</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Taipei Veterans General Hospital</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Taipei</city>
                                    <state></state>
                                    <country>Taiwan</country>
                                    <postalCode>112</postalCode>
                                </address>
                            </site>
                        </sites>
                    </clinicalTrial>
                </clinicalTrials>
            </treatment>
        </alteration>
        <alteration>
            <type>cnv</type>
            <gene>EGFR</gene>
            <name>Amplification</name>
            <method>amplification</method>
            <detected>true</detected>
            <value>+</value>
            <cnv>
                <copyNumber>2.4</copyNumber>
                <amplification>low</amplification>
            </cnv>
            <treatment>
                <otherTherapies>Necitumumab</otherTherapies>
                <trialAvailable>true</trialAvailable>
                <therapies>
                    <therapy>
                        <drug>SYN004</drug>
                        <tradeName></tradeName>
                        <rationale>Anti-Egfr monoclonal antibody.</rationale>
                        <disease>Solid Tumor</disease>
                        <status>Phase 1</status>
                        <otherDiseases>---
- Lung squamous cell carcinoma
</otherDiseases>
                        <otherStatus>Phase 1</otherStatus>
                    </therapy>
                    <therapy>
                        <drug>Nimotuzumab</drug>
                        <tradeName>Theraloc</tradeName>
                        <rationale>Egfr inhibitory antibody.</rationale>
                        <disease>Non-small cell lung carcinoma (NSCLC)</disease>
                        <status>Phase 3</status>
                        <otherDiseases>---
- Gastric carcinoma
- Glioblastoma
- Glioma
- Pancreatic carcinoma
- Head and neck carcinoma
- Gastroesophageal junction carcinoma
- Esophageal carcinoma
- Cervical carcinoma
</otherDiseases>
                        <otherStatus>Phase 3</otherStatus>
                    </therapy>
                    <therapy>
                        <drug>Dacomitinib</drug>
                        <tradeName></tradeName>
                        <rationale>Pan-ErbB family tyrosine kinase inhibitor.</rationale>
                        <disease>Non-small cell lung carcinoma (NSCLC)</disease>
                        <status>Phase 3</status>
                        <otherDiseases>---
- Gastric carcinoma
- Glioblastoma
- Glioma
- Pancreatic carcinoma
- Head and neck carcinoma
- Cutaneous squamous cell carcinoma
- Esophageal carcinoma
- Penile carcinoma
- Colorectal carcinoma (CRC)
</otherDiseases>
                        <otherStatus>Phase 2</otherStatus>
                    </therapy>
                    <therapy>
                        <drug>KBP-5209</drug>
                        <tradeName></tradeName>
                        <rationale>ErbB family inhibitor.</rationale>
                        <disease>Solid Tumor</disease>
                        <status>Phase 1</status>
                        <otherStatus></otherStatus>
                    </therapy>
                    <therapy>
                        <drug>Pyrotinib</drug>
                        <tradeName></tradeName>
                        <rationale>Egfr/Her2 kinase inhibitor.</rationale>
                        <disease>Non-small cell lung carcinoma (NSCLC)</disease>
                        <status>Phase 2</status>
                        <otherDiseases>---
- Breast carcinoma
</otherDiseases>
                        <otherStatus>Phase 3</otherStatus>
                    </therapy>
                    <therapy>
                        <drug>Icotinib</drug>
                        <tradeName>Conmana</tradeName>
                        <rationale>Egfr inhibitor.</rationale>
                        <disease>Non-small cell lung carcinoma (NSCLC)</disease>
                        <status>Phase 3</status>
                        <otherDiseases>---
- Esophageal carcinoma
</otherDiseases>
                        <otherStatus>Phase 2</otherStatus>
                    </therapy>
                    <therapy>
                        <drug>ASP8273</drug>
                        <tradeName></tradeName>
                        <rationale>EGFR mutant-specific inhibitor.</rationale>
                        <disease>Non-small cell lung carcinoma (NSCLC)</disease>
                        <status>Phase 3</status>
                        <otherDiseases>---
- Solid Tumor
</otherDiseases>
                        <otherStatus>Phase 1</otherStatus>
                    </therapy>
                    <therapy>
                        <drug>Necitumumab</drug>
                        <tradeName>Portrazza</tradeName>
                        <rationale>Anti-Egfr monoclonal antibody.</rationale>
                        <disease>Non-small cell lung carcinoma (NSCLC)</disease>
                        <status>Phase 3</status>
                        <otherDiseases>---
- Lung squamous cell carcinoma
</otherDiseases>
                        <otherStatus>FDA Approved</otherStatus>
                    </therapy>
                    <therapy>
                        <drug>Neratinib</drug>
                        <tradeName></tradeName>
                        <rationale>Egfr/Her2/ErbB4 inhibitor.</rationale>
                        <disease>Non-small cell lung carcinoma (NSCLC)</disease>
                        <status>Phase 2</status>
                        <otherDiseases>---
- Breast carcinoma
</otherDiseases>
                        <otherStatus>Phase 3</otherStatus>
                    </therapy>
                    <therapy>
                        <drug>TH4000</drug>
                        <tradeName></tradeName>
                        <rationale>Hypoxia-activated Egfr tyrosine kinase inhibitor.</rationale>
                        <disease>Non-small cell lung carcinoma (NSCLC)</disease>
                        <status>Phase 2</status>
                        <otherDiseases>---
- Head and neck squamous cell carcinoma (HNSCC)
</otherDiseases>
                        <otherStatus>Phase 2</otherStatus>
                    </therapy>
                    <therapy>
                        <drug>Varlitinib</drug>
                        <tradeName></tradeName>
                        <rationale>Egfr/Her2 inhibitor.</rationale>
                        <disease></disease>
                        <status></status>
                        <otherDiseases>---
- Gastric carcinoma
- Pancreatic carcinoma
</otherDiseases>
                        <otherStatus>Phase 2</otherStatus>
                    </therapy>
                </therapies>
                <clinicalRelevances>
                    <clinicalRelevance>
                        <roleInDisease>The presence of an EGFR abnormality (mutation, amplification, or overexpression) can result in an overabundance or overactivity of Egfr protein, which can lead to excessive proliferation (Ciardiello and Tortora, 2008; 18337605). EGFR mutations in NSCLC have been reported to occur more frequently in women, never-smokers, and in patients with adenocarcinoma histology (Rizzo et al., 2016; 25956936, Lee et al., 2015; 26359571, Naderi et al., 2015; 26362141, Zhou et al., 2016; 27039821, Lee et al., 2016; 26992209, Zhang et al., 2016; 27738317).</roleInDisease>
                        <drugSensitivity>EGFR amplification or increased copy number have been reported to be associated with increased sensitivity to Egfr targeted therapies in studies of lung cancer, whereas studies in colorectal cancer (CRC) patients have been mixed; efficacy in patients with CRC is dependent on the absence of KRAS and NRAS mutations (Tsao et al., 2005; 16014883, Bell et al., 2005; 16204011, Hirsch et al., 2005; 15998906, Ålgars et al., 2011; 21694725, Sartore-Bianchi et al., 2007; 17664472, Yang et al., 2012; 22897982). The Egfr TKIs erlotinib, afatinib, and gefitinib have been approved by the FDA for the treatment of EGFR mutant non-small cell lung cancer (NSCLC) (Shepherd et al., 2005; 16014882, Rosell et al., 2012; 22285168, Sequist et al., 2013; 23816960, Douillard et al., 2014; 24263064, Mok et al., 2009; 19692680). Erlotinib, in combination with gemcitabine, has also been approved by the FDA for the treatment of locally advanced, unresectable, or metastatic pancreatic cancer (Moore et al., 2007; 17452677, Senderowicz et al., 2007; 18247017). Anti-Egfr monoclonal antibodies are also approved in some indications, including cetuximab, which is an approved therapy for HNSCC and colorectal cancer, panitumumab, which is approved in colorectal cancer, and necitumumab, which has received approval for the treatment of advanced squamous NSCLC (Cunningham et al., 2004; 15269313, Vermorken et al., 2008; 18784101, Van Cutsem et al., 2007; 17470858, Thatcher et al., 2015; 26045340). For NSCLC patients with metastatic disease and tumors harboring a sensitizing EGFR mutation, the NCCN guidelines (v.2.2016) suggest treating with erlotinib, afatinib, or gefitinib if the alteration is discovered prior to first-line chemotherapy or interrupting/completing current therapy and treating with erlotinib, afatinib, or gefitinib if the alteration is discovered during first-line chemotherapy. However, EGFR T790M, also detected in this tumor, has been associated with resistance to the Egfr tyrosine kinase inhibitors erlotinib, gefitinib, and afatinib (Greulich et al., 2005; 16187797, Suda et al., 2009; 19096299, Denis et al., 2015; 25668228, Wu et al., 2016; 26862733, Yang et al., 2015; 26051236, Kim et al., 2012; 22228822).</drugSensitivity>
                        <drugResistance>Some patients with EGFR-mutant NSCLC exhibit resistance to Egfr inhibition; resistance has been associated with insertions in EGFR exon 20, the T790M mutation in EGFR, and amplification of the gene MET (Engelman et al., 2007; 17463250, Greulich et al., 2005; 16187797, Kwak et al., 2005; 15897464). Third generation irreversible Egfr TKIs that target the EGFR T790M mutation have shown efficacy in T790M-mutant NSCLC and are under clinical investigation, including osimertinib, which has received FDA-approval for the treatment of EGFR T790M-mutant metastatic NSCLC (Jänne et al., 2011; 21220471, Jänne et al., 2015; 25923549, Greig, 2016; 26729184, Yang et al., 2016; 27198353, Wang et al., 2016; 27071706). Several studies have reported that resistance to Egfr TKIs in NSCLC is mediated by the transformation of NSCLC cell types to those of SCLC with neuroendocrine features (Watanabe et al., 2013; 24012411, Chang et al., 2013; 24101933, Popat et al., 2013; 23312887, Sequist et al., 2011; 21430269).</drugResistance>
                    </clinicalRelevance>
                </clinicalRelevances>
                <biologicalSignificances>
                    <biologicalSignificance>
                        <content>EGFR-amplification is an activating alteration. EGFR activating mutations or amplification may predict sensitivity to Egfr-targeted therapies, including inhibitors of multiple ErbB family members, and several have received FDA approval in some tumor types (Mok et al., 2009; 19692680, Rosell et al., 2009; 19692684, Tsao et al., 2005; 16014883). Egfr activation or overexpression may also lead to activation of the PI3K and MAPK pathway and may confer sensitivity to PI3K and MAPK pathway inhibitors (Bancroft et al., 2002; 11992543). EGFR T790M, also detected in this tumor, has been associated with resistance to the Egfr tyrosine kinase inhibitors erlotinib, gefitinib, and afatinib (Greulich et al., 2005; 16187797, Suda et al., 2009; 19096299, Denis et al., 2015; 25668228, Yang et al., 2015; 26051236, Kim et al., 2012; 22228822).</content>
                        <molecularFunction>High-level EGFR gene amplification has been correlated with elevated Egfr protein expression, as measured by immunohistochemistry, although this correlation is not consistent for low-level gene amplification (Hemmings et al., 2009; 19404848, Liang et al., 2010; 20637128, Yang et al., 2012; 22490401, Bhargava et al., 2005; 15920544, Miyai et al., 2010; 20608935).</molecularFunction>
                        <incidence>Putative high-level amplification of EGFR has been reported in 5.4-6.5% of Lung adenocarcinoma cases (cBioPortal for Cancer Genomics, Apr 2017). Amplification of EGFR has been reported in 6.4-10% of non-small cell lung carcinoma (NSCLC) samples in several large studies (Park et al., 2012; 22207554, Grob et al., 2013; 23238037, Liang et al., 2010; 20637128, Zhang et al., 2014; 24452282, Schrock et al., 2016; 27343443). However, smaller studies of less than 100 samples have detected higher incidences of EGFR amplification in NSCLC, citing it in 35-64% of cases, with one study reporting EGFR amplification in 72% (16/22) and 64% (16/25) of adenocarcinoma and squamous cell carcinoma samples, respectively (Russell et al., 2014; 24300726, Liang et al., 2010; 20637128, Tochigi et al., 2011; 21502435, Oakley and Chiosea, 2011; 21587084, Jia et al., 2015; 26400330). One study reported positive EGFR mRNA expression in the peripheral blood of 69% (29/42) of non-small cell lung carcinoma (NSCLC) patients, as compared with 12.5% (5/40) of control patients without lung cancer (Zhang et al., 2014; 24396405). Egfr expression has been reported in 19-69% of NSCLC cases (Ludovini et al., 2013; 23314677, Dobashi et al., 2011; 21040950, Traynor et al., 2013; 23628526, Watzka et al., 2010; 20353893, Liang et al., 2010; 20637128, Grob et al., 2013; 23238037, Park et al., 2012; 22207554, Hao et al., 2015; 26648997).</incidence>
                    </biologicalSignificance>
                </biologicalSignificances>
                <clinicalTrials>
                    <clinicalTrial>
                        <trialId>NCT01552434</trialId>
                        <title>Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid or Cetuximab in Patients With Advanced Malignancy and Other Indications</title>
                        <phase>Phase 1</phase>
                        <contact>Overall contact: Sarina Piha-Paul, MD, 713-563-1930</contact>
                        <sites>
                            <site>
                                <center>University of Texas MD Anderson Cancer Center</center>
                                <contact></contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Houston</city>
                                    <state>Texas</state>
                                    <country>United States</country>
                                    <postalCode>77030</postalCode>
                                </address>
                            </site>
                        </sites>
                    </clinicalTrial>
                    <clinicalTrial>
                        <trialId>NCT02648490</trialId>
                        <title>An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers</title>
                        <phase>Phase 1</phase>
                        <contact>Overall contact: Weidong Jiang, Ph.D., wjiang@henlix.com, (510) 445-0305</contact>
                        <sites>
                            <site>
                                <center>Henlix, Inc.</center>
                                <contact>Weidong Jiang, Ph.D.</contact>
                                <investigator></investigator>
                                <status>Not yet recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Fremont</city>
                                    <state>California</state>
                                    <country>United States</country>
                                    <postalCode>94538</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Linkou Chang Gung Memorial Hospital</center>
                                <contact>Wen-Neng Ueng</contact>
                                <investigator>Ming-Mo Hou, MD</investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Taoyuan</city>
                                    <state></state>
                                    <country>Taiwan</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                        </sites>
                    </clinicalTrial>
                    <clinicalTrial>
                        <trialId>NCT02448797</trialId>
                        <title>Icotinib Versus Vinorelbine/Platinum as Adjuvant Therapy in Stage II-IIIA Non-small Cell Lung Cancer With EGFR-mutation</title>
                        <phase>Phase 3</phase>
                        <contact>Overall contact: Caicun Zhou, MD, 13301825532</contact>
                        <sites>
                            <site>
                                <center>The First Affiliated Hospital of Medical School of Zhejiang University</center>
                                <contact>Zhou Jianying, M.D.</contact>
                                <investigator>Zhou Jianying, M.D.</investigator>
                                <status>Recruiting</status>
                                <prioritization>clinically</prioritization>
                                <address>
                                    <city>Hangzhou</city>
                                    <state>Zhejiang</state>
                                    <country>China</country>
                                    <postalCode>310000</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>307 Hospital of PLA</center>
                                <contact></contact>
                                <investigator>Xiao-qing Liu, M.D.</investigator>
                                <status>Recruiting</status>
                                <prioritization>clinically</prioritization>
                                <address>
                                    <city>Beijing</city>
                                    <state>Beijing</state>
                                    <country>China</country>
                                    <postalCode>100071</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Fujian Provincal Cancer Hospital</center>
                                <contact>Huang Cheng, M.D.</contact>
                                <investigator>Huang Cheng, M.D.</investigator>
                                <status>Recruiting</status>
                                <prioritization>clinically</prioritization>
                                <address>
                                    <city>Fuzhou</city>
                                    <state>Fujian</state>
                                    <country>China</country>
                                    <postalCode>350014</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Shanghai Pulmonary Hospital</center>
                                <contact></contact>
                                <investigator>Cai-Cun Zhou</investigator>
                                <status>Recruiting</status>
                                <prioritization>clinically</prioritization>
                                <address>
                                    <city>Shanghai</city>
                                    <state>Shanghai</state>
                                    <country>China</country>
                                    <postalCode>200433</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Shenzhen People's Hospital</center>
                                <contact>Zheng Wang, MD</contact>
                                <investigator>Zheng Wang, MD</investigator>
                                <status>Recruiting</status>
                                <prioritization>clinically</prioritization>
                                <address>
                                    <city>Shenzhen</city>
                                    <state>Guangdong</state>
                                    <country>China</country>
                                    <postalCode>518020</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>The First Affiliated Hospital Of Guangzhou Medical Collage</center>
                                <contact>He Jianxing</contact>
                                <investigator>He Jianxing, M.D.</investigator>
                                <status>Recruiting</status>
                                <prioritization>clinically</prioritization>
                                <address>
                                    <city>Guangzhou</city>
                                    <state>Guangdong</state>
                                    <country>China</country>
                                    <postalCode>510120</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>The First Hospital of China Medical University</center>
                                <contact>Liu Yunpeng, M.D.</contact>
                                <investigator>Liu Yunpeng, M.D.</investigator>
                                <status>Recruiting</status>
                                <prioritization>clinically</prioritization>
                                <address>
                                    <city>Shenyang</city>
                                    <state>Liaoning</state>
                                    <country>China</country>
                                    <postalCode>110001</postalCode>
                                </address>
                            </site>
                        </sites>
                    </clinicalTrial>
                    <clinicalTrial>
                        <trialId>NCT02496663</trialId>
                        <title>EGFR Inhibitor AZD9291 and Necitumumab in Treating Patients With EGFR-Positive Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor</title>
                        <phase>Phase 1</phase>
                        <contact></contact>
                        <sites>
                            <site>
                                <center>University of California Davis Comprehensive Cancer Center</center>
                                <contact>Jonathan W. Riess</contact>
                                <investigator>Jonathan W. Riess</investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Sacramento</city>
                                    <state>California</state>
                                    <country>United States</country>
                                    <postalCode>95817</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>City of Hope Comprehensive Cancer Center LAO</center>
                                <contact>Jonathan W. Riess</contact>
                                <investigator>Jonathan W. Riess</investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Duarte</city>
                                    <state>California</state>
                                    <country>United States</country>
                                    <postalCode>91010</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>City of Hope Comprehensive Cancer Center</center>
                                <contact>Jonathan W. Riess</contact>
                                <investigator>Jonathan W. Riess</investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Duarte</city>
                                    <state>California</state>
                                    <country>United States</country>
                                    <postalCode>91010</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Dana-Farber Cancer Institute</center>
                                <contact>Pasi A. Janne</contact>
                                <investigator>Pasi A. Janne</investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Boston</city>
                                    <state>Massachusetts</state>
                                    <country>United States</country>
                                    <postalCode>02215</postalCode>
                                </address>
                            </site>
                        </sites>
                    </clinicalTrial>
                    <clinicalTrial>
                        <trialId>NCT02736513</trialId>
                        <title>Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases</title>
                        <phase>Phase 2</phase>
                        <contact>Overall contact: Nir Peled, MD PhD FCCP, nirp@clalit.org.il</contact>
                        <sites>
                            <site>
                                <center>Rabin Medical Center</center>
                                <contact>Nir Peled, MD PhD FCCP</contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Petach Tikva</city>
                                    <state></state>
                                    <country>Israel</country>
                                    <postalCode>49100</postalCode>
                                </address>
                            </site>
                        </sites>
                    </clinicalTrial>
                    <clinicalTrial>
                        <trialId>NCT02789345</trialId>
                        <title>A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer</title>
                        <phase>Phase 1</phase>
                        <contact>Overall contact: There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or, 1-317-615-4559</contact>
                        <sites>
                            <site>
                                <center>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</center>
                                <contact>Eli Lilly and Company</contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Seoul</city>
                                    <state></state>
                                    <country>Korea, Republic of</country>
                                    <postalCode>05505</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</center>
                                <contact>Eli Lilly and Company</contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Villejuif</city>
                                    <state></state>
                                    <country>France</country>
                                    <postalCode>94805</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</center>
                                <contact>Eli Lilly and Company</contact>
                                <investigator>Pilar Garrido López</investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Madrid</city>
                                    <state></state>
                                    <country>Spain</country>
                                    <postalCode>28034</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Memorial Sloan Kettering Cancer Center</center>
                                <contact></contact>
                                <investigator>Helena Yu</investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>New York</city>
                                    <state>New York</state>
                                    <country>United States</country>
                                    <postalCode>10065</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</center>
                                <contact>Eli Lilly and Company</contact>
                                <investigator></investigator>
                                <status>Not yet recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Hong Kong</city>
                                    <state></state>
                                    <country>Hong Kong</country>
                                    <postalCode></postalCode>
                                </address>
                            </site>
                            <site>
                                <center>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</center>
                                <contact>Eli Lilly and Company</contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Seongnam</city>
                                    <state></state>
                                    <country>Korea, Republic of</country>
                                    <postalCode>13496</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Fairfax Northern Virginia Hematology Oncology,PC</center>
                                <contact></contact>
                                <investigator>Alexander Spira</investigator>
                                <status>Not yet recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Fairfax</city>
                                    <state>Virginia</state>
                                    <country>United States</country>
                                    <postalCode>22031</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</center>
                                <contact>Eli Lilly and Company</contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Cheong Ju-City</city>
                                    <state></state>
                                    <country>Korea, Republic of</country>
                                    <postalCode>28644</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Tennessee Oncology PLLC</center>
                                <contact></contact>
                                <investigator>Melissa Johnson</investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Nashville</city>
                                    <state>Tennessee</state>
                                    <country>United States</country>
                                    <postalCode>37203</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</center>
                                <contact>Eli Lilly and Company</contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Madrid</city>
                                    <state></state>
                                    <country>Spain</country>
                                    <postalCode>28041</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</center>
                                <contact>Eli Lilly and Company</contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Tainan</city>
                                    <state></state>
                                    <country>Taiwan</country>
                                    <postalCode>70403</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Palm Beach Cancer Institue</center>
                                <contact></contact>
                                <investigator>Todd Gersten</investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>West Palm Beach</city>
                                    <state>Florida</state>
                                    <country>United States</country>
                                    <postalCode>33401</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</center>
                                <contact>Eli Lilly and Company</contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Seoul</city>
                                    <state></state>
                                    <country>Korea, Republic of</country>
                                    <postalCode>06351</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>Florida Cancer Specialists</center>
                                <contact></contact>
                                <investigator>Michael McCleod</investigator>
                                <status>Not yet recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Fort Myers</city>
                                    <state>Florida</state>
                                    <country>United States</country>
                                    <postalCode>33916</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</center>
                                <contact>Eli Lilly and Company</contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Toulouse</city>
                                    <state></state>
                                    <country>France</country>
                                    <postalCode>31059</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</center>
                                <contact>Eli Lilly and Company</contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Sevilla</city>
                                    <state></state>
                                    <country>Spain</country>
                                    <postalCode>41013</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</center>
                                <contact>Eli Lilly and Company</contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Taipei</city>
                                    <state></state>
                                    <country>Taiwan</country>
                                    <postalCode>10048</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</center>
                                <contact>Eli Lilly and Company</contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Orbassano</city>
                                    <state></state>
                                    <country>Italy</country>
                                    <postalCode>10043</postalCode>
                                </address>
                            </site>
                            <site>
                                <center>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</center>
                                <contact>Eli Lilly and Company</contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>regionally</prioritization>
                                <address>
                                    <city>Seoul</city>
                                    <state></state>
                                    <country>Korea, Republic of</country>
                                    <postalCode>06591</postalCode>
                                </address>
                            </site>
                        </sites>
                    </clinicalTrial>
                    <clinicalTrial>
                        <trialId>NCT01996098</trialId>
                        <title>Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR Mutation</title>
                        <phase>Phase 3</phase>
                        <contact>Overall contact: Si-Yu Wang, MD, wsysums@163.net, + 86 20 87343439</contact>
                        <sites>
                            <site>
                                <center>Sun Yat-sen University Cancer Center</center>
                                <contact>Si-Yu Wang, MD</contact>
                                <investigator></investigator>
                                <status>Recruiting</status>
                                <prioritization>clinically</prioritization>
                                <address>
                                    <city>Guangzhou</city>
                                    <state>Guangdong</state>
                                    <country>China</country>
                                    <postalCode>510060</postalCode>
                                </address>
                            </site>
                        </sites>
                    </clinicalTrial>
                </clinicalTrials>
            </treatment>
        </alteration>
        <alteration>
            <type>snv</type>
            <gene>ERBB2</gene>
            <name>T1124T</name>
            <method>substitution</method>
            <detected>true</detected>
            <synonymous>true</synonymous>
            <value>1.3%</value>
            <snv>
                <cfdnaPercentage>1.3</cfdnaPercentage>
                <exon>26</exon>
                <cdna>c.3372T>A</cdna>
                <chromosome>17</chromosome>
                <aminoAcidMutation>T1124T</aminoAcidMutation>
                <nucleotideMutation>T>A</nucleotideMutation>
                <position>37883760</position>
                <transcriptId>NM_004448.2</transcriptId>
                <reportingCategory>protein_coding</reportingCategory>
            </snv>
        </alteration>
    </alterations>
    <definitions>
        <definition>
            <term>Amplification:</term>
            <description>Gene amplification results in increased copies of the gene present in the cfDNA. As the absolute number of copies in circulation is dependent on both tumor fraction and the magnitude of the tumor amplification, amplifications are reported on a semi-quantitative scale:

Positive (+): Amplification magnitude is in the lower 50th percentile of samples with amplifications.
Strongly Positive (++): Amplification magnitude is in the 50th to 90th percentile.
Very Strongly Positive (+++): Amplification magnitude is in the top 10th percentile. Guardant360 detects amplifications in the genes listed in Table 1.</description>
        </definition>
        <definition>
            <term>Deletion (Del):</term>
            <description>The following alteration was detected in this patient: EGFR E746_A750del. Guardant360 detects short deletions in exons of certain genes (see Table 1), including potential splice site-disrupting events.</description>
        </definition>
    </definitions>
    <interpretation>
        <description>Somatic alterations were detected in the circulating cell-free DNA isolated from this patient’s blood specimen, some of which have been associated with either increased or reduced clinical response to specific treatments.
Amplification was detected in the circulating cell-free DNA isolated from this patient’s blood specimen for the annotated gene(s). Unlike tissue-based gene amplification tests (e.g. IHC or FISH), Guardant360 assesses the total representation of a given gene in all circulating cell-free DNA present in the patient’s blood sample including material derived from the tumor and healthy tissue alike. As such, the absolute level of amplification present in the blood depends both on the tumor-derived cfDNA content and on the degree of amplification within that fraction and cannot be inferred from bulk cfDNA interrogation. For example, a positive Guardant360 test could represent a small population of cells with extremely high levels of the detected gene amplification. Alternatively, it could represent a large population of cells with low to medium levels of the detected gene amplifications. The exact correlation between amplification detected by Guardant360 compared to IHC or FISH and how each test differentially guides patient management is an area of active investigation.</description>
    </interpretation>
    <methodAndLimitations>
        <description>Guardant360 sequences 73 genes to identify somatic genomic alterations in cancer- associated variants with high sensitivity. Cell-free DNA is extracted from plasma, and genomic alterations are analyzed by massively parallel sequencing of amplified target genes using the Illumina® HiSeq® 2500 or Illumina® NextSeq® 500 platforms and hg19 as the reference genome. For certain genes, all exons are sequenced as such sequencing coverage has been shown to have clinical utility. For another set of genes, sequencing coverage includes those exons with a previously reported somatic mutation. Synonymous substitutions are reported if present, although the clinical relevance of such variants is not clear. The minimum detectable mutant allele fraction (limit of detection) is dependent on the patient’s sample cell-free DNA concentration, which can vary from less than 10 to over 1000 genomic equivalents per mL of peripheral blood. Guardant360 is validated to detect gene amplifications in specific genes in Table 1; amplification may not be detected in samples with low amounts of cell-free DNA and/or low-level gene amplifications. Certain sample characteristics may interfere with the accurate determination of copy number variants. The types of genomic alterations detected by Guardant360 include single nucleotide variations, amplifications, fusions (in ALK, FGFR2, FGFR3, RET, ROS1, and NTRK1 genes), short insertions/deletions, and splice site-disrupting events (such as MET exon 14 skipping mutations) (see Table 1). This version of the Guardant360 test is not validated for the detection of other types of genomic alterations, such as complex rearrangements, gene deletions, or indels in genes not listed in Table 1. Certain sample or variant characteristics may result in reduced analytic sensitivity, such as low sample quality or improper collection. Guardant360 cannot discern the source of the circulating cfDNA, and for some variants in the range of ~40 to 60% cfDNA, the test cannot easily distinguish germline variants from somatic alterations. Guardant360 is not validated for the detection of germline or de novo variants that are associated with hereditary cancer risk.</description>
    </methodAndLimitations>
    <about>
        <description>Guardant360 (Test) was developed and its performance characteristics were determined by Guardant Health, Inc. This Test has not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. This Test may be used for clinical purposes and should not be regarded as investigational or for research only. Guardant Health’s clinical reference laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical laboratory testing.
Guardant360 is a next-generation sequencing-based assay that identifies potential tumor-related (somatic) genomic alterations within 73 cancer-related genes through analysis of cell-free DNA that is circulating in blood. These somatic alterations or lack of detected somatic alterations, as the case may be, are reported to a patient’s treating medical professional in this report (Report). The Report should be considered in context with other clinical criteria (e.g. patient history, physical exam), as well as laboratory, pathology, and imaging studies by a qualified medical professional prior to initiating or changing a patient’s treatment plan. Patient management decisions must be based on the independent medical judgment of the treating medical professional; specific clinical situations may warrant continued usage of certain drugs contrary to what is provided on the Report. Moreover, drugs referenced in this Report may not be suitable for a particular patient. The selection of any, all, or none of the drugs associated with potential clinical benefit (or potential lack of clinical benefit) is entirely at the discretion of the treating medical professional. The Guardant360 Test and accompanying Report are not intended to be used as the sole means for clinical diagnosis or patient management decisions. Guardant360 is not validated for the detection of germline or de novo variants that are associated with hereditary cancer risk. The Guardant360 Tumor Response Map is a graphical display of historic patient data. Due to analytic or reporting changes in the Test over time (e.g. genes on the panel, test sensitivity, etc.), the graphical display of the historic data on this report may need to be evaluated in context of the previous reports.
The Guardant360 Report may include information on drugs and drug candidates undergoing clinical investigation. This information is derived from peer-reviewed studies and other publicly available databases and may include associations between a detected genomic alteration or lack of a detected genomic alteration, as applicable, and drug(s) with possible clinical effect (or possible lack of clinical effect). Some drugs listed in this Report may not be approved or cleared by the FDA for a particular use. Guardant Health makes no endorsement, express or implied, of any product, physician, or procedure contained in this Report. The Report includes this information on drugs and drug-candidates based only upon the diagnosis as written by the authorized medical professional on the submitted test request form; this information is not based on any supplemental information provided by the requesting medical professional, including pathology reports or other molecular studies. The medical professional should contact Guardant Health if an alternative diagnosis should be used to generate information on drugs and drug candidates undergoing clinical investigation.
The detection of a genomic alteration does not necessarily mean there is clinical benefit (or lack thereof) of any medication or treatment plan. The absence of a detected genomic alteration does not necessarily mean there would be no clinical benefit of a medication or treatment plan. This Report makes no promises or guarantees that a particular medication will affect (or not affect) the clinical outcome of any patient.
Lists of genomic alterations or drugs on this Report are not ranked in order of potential or predicted efficacy. Drugs with potential clinical effect (or potential lack of clinical effect) are not evaluated for source or level of published evidence.</description>
        <testSite>
            <name>Testing performed at: Guardant Health</name>
            <info>Laboratory Director: Arthur Baca, MD PhD | CLIA ID: 05D2070300 | CAP #: 8765297 | 505 Penobscot Drive, Redwood City, CA, 94063, United States</info>
        </testSite>
    </about>
    <genes>
        <gene>
            <name>AKT1</name>
        </gene>
        <gene>
            <name>ALK</name>
            <category>fusion</category>
        </gene>
        <gene>
            <name>APC</name>
            <category>indel</category>
        </gene>
        <gene>
            <name>AR</name>
            <category>cnv</category>
        </gene>
        <gene>
            <name>ARAF</name>
        </gene>
        <gene>
            <name>ARID1A</name>
            <category>indel</category>
        </gene>
        <gene>
            <name>ATM</name>
            <category>indel</category>
        </gene>
        <gene>
            <name>BRAF</name>
            <category>cnv</category>
        </gene>
        <gene>
            <name>BRCA1</name>
            <category>indel</category>
        </gene>
        <gene>
            <name>BRCA2</name>
            <category>indel</category>
        </gene>
        <gene>
            <name>CCND1</name>
            <category>cnv</category>
        </gene>
        <gene>
            <name>CCND2</name>
            <category>cnv</category>
        </gene>
        <gene>
            <name>CCNE1</name>
            <category>cnv</category>
        </gene>
        <gene>
            <name>CDH1</name>
            <category>indel</category>
        </gene>
        <gene>
            <name>CDK4</name>
            <category>cnv</category>
        </gene>
        <gene>
            <name>CDK6</name>
            <category>cnv</category>
        </gene>
        <gene>
            <name>CDKN2A</name>
            <category>indel</category>
        </gene>
        <gene>
            <name>CTNNB1</name>
        </gene>
        <gene>
            <name>DDR2</name>
        </gene>
        <gene>
            <name>EGFR</name>
            <category>indel</category>
            <category>cnv</category>
        </gene>
        <gene>
            <name>ERBB2</name>
            <protein>HER2</protein>
            <category>indel</category>
            <category>cnv</category>
        </gene>
        <gene>
            <name>ESR1</name>
        </gene>
        <gene>
            <name>EZH2</name>
        </gene>
        <gene>
            <name>FBXW7</name>
        </gene>
        <gene>
            <name>FGFR1</name>
            <category>cnv</category>
        </gene>
        <gene>
            <name>FGFR2</name>
            <category>cnv</category>
            <category>fusion</category>
        </gene>
        <gene>
            <name>FGFR3</name>
            <category>fusion</category>
        </gene>
        <gene>
            <name>GATA3</name>
            <category>indel</category>
        </gene>
        <gene>
            <name>GNA11</name>
        </gene>
        <gene>
            <name>GNAQ</name>
        </gene>
        <gene>
            <name>GNAS</name>
        </gene>
        <gene>
            <name>HNF1A</name>
        </gene>
        <gene>
            <name>HRAS</name>
        </gene>
        <gene>
            <name>IDH1</name>
        </gene>
        <gene>
            <name>IDH2</name>
        </gene>
        <gene>
            <name>JAK2</name>
        </gene>
        <gene>
            <name>JAK3</name>
        </gene>
        <gene>
            <name>KIT</name>
            <category>indel</category>
            <category>cnv</category>
        </gene>
        <gene>
            <name>KRAS</name>
            <category>cnv</category>
        </gene>
        <gene>
            <name>MAP2K1</name>
        </gene>
        <gene>
            <name>MAP2K2</name>
        </gene>
        <gene>
            <name>MAPK1</name>
        </gene>
        <gene>
            <name>MAPK3</name>
        </gene>
        <gene>
            <name>MET</name>
            <category>indel</category>
            <category>cnv</category>
        </gene>
        <gene>
            <name>MLH1</name>
            <category>indel</category>
        </gene>
        <gene>
            <name>MPL</name>
        </gene>
        <gene>
            <name>MTOR</name>
            <category>indel</category>
        </gene>
        <gene>
            <name>MYC</name>
            <category>cnv</category>
        </gene>
        <gene>
            <name>NF1</name>
            <category>indel</category>
        </gene>
        <gene>
            <name>NFE2L2</name>
        </gene>
        <gene>
            <name>NOTCH1</name>
        </gene>
        <gene>
            <name>NPM1</name>
        </gene>
        <gene>
            <name>NRAS</name>
        </gene>
        <gene>
            <name>NTRK1</name>
            <category>fusion</category>
        </gene>
        <gene>
            <name>NTRK3</name>
        </gene>
        <gene>
            <name>PDGFRA</name>
            <category>indel</category>
            <category>cnv</category>
        </gene>
        <gene>
            <name>PIK3CA</name>
            <category>cnv</category>
        </gene>
        <gene>
            <name>PTEN</name>
            <category>indel</category>
        </gene>
        <gene>
            <name>PTPN11</name>
        </gene>
        <gene>
            <name>RAF1</name>
            <category>cnv</category>
        </gene>
        <gene>
            <name>RB1</name>
            <category>indel</category>
        </gene>
        <gene>
            <name>RET</name>
            <category>fusion</category>
        </gene>
        <gene>
            <name>RHEB</name>
        </gene>
        <gene>
            <name>RHOA</name>
        </gene>
        <gene>
            <name>RIT1</name>
        </gene>
        <gene>
            <name>ROS1</name>
            <category>fusion</category>
        </gene>
        <gene>
            <name>SMAD4</name>
            <category>indel</category>
        </gene>
        <gene>
            <name>SMO</name>
        </gene>
        <gene>
            <name>STK11</name>
            <category>indel</category>
        </gene>
        <gene>
            <name>TERT</name>
            <category>promoter</category>
        </gene>
        <gene>
            <name>TP53</name>
            <category>indel</category>
        </gene>
        <gene>
            <name>TSC1</name>
            <category>indel</category>
        </gene>
        <gene>
            <name>VHL</name>
            <category>indel</category>
        </gene>
    </genes>
    <references>
        <reference>
            <referenceId>ESMO 2016, Abstract 379P</referenceId>
            <title>Phase II studies of AZD1775, a WEE1 kinase inhibitor, and chemotherapy in non-small-cell lung cancer (NSCLC): Lead-in cohort results</title>
            <authors>Spigel DR, Dakhil S, Beck JT</authors>
            <journal>Annals of Oncology</journal>
            <issue>6</issue>
            <page>114-135</page>
            <year>2016</year>
        </reference>
        <reference>
            <referenceId>20107315</referenceId>
            <title>MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil.</title>
            <authors>Hirai H, Arai T, Okada M, Nishibata T, Kobayashi M, Sakai N, Imagaki K, Ohtani J, Sakai T, Yoshizumi T, Mizuarai S, Iwasawa Y, Kotani H</authors>
            <journal>Cancer biology &amp; therapy</journal>
            <issue>7</issue>
            <page>514-22</page>
            <year>2010</year>
        </reference>
        <reference>
            <referenceId>17613438</referenceId>
            <title>Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy.</title>
            <authors>Li D, Shimamura T, Ji H, Chen L, Haringsma H, McNamara K, Liang M, Perera S, Zaghlul S, Borgman C, Kubo S, Takahashi M, Sun Y, Chirieac L, Padera R, Lindeman N, Jänne P, Thomas R, Meyerson M, Eck M, Engelman J, Shapiro G, Wong K</authors>
            <journal>Cancer cell</journal>
            <issue>1</issue>
            <page>81-93</page>
            <year>2007</year>
        </reference>
        <reference>
            <referenceId>23628526</referenceId>
            <title>Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer.</title>
            <authors>Traynor A, Weigel T, Oettel K, Yang D, Zhang C, Kim K, Salgia R, Iida M, Brand T, Hoang T, Campbell T, Hernan H, Wheeler D</authors>
            <journal>Lung cancer (Amsterdam, Netherlands)</journal>
            <issue>1</issue>
            <page>138-41</page>
            <year>2013</year>
        </reference>
        <reference>
            <referenceId>7891710</referenceId>
            <title>Interaction of p53 with its consensus DNA-binding site.</title>
            <authors>Wang Y, Schwedes J, Parks D, Mann K, Tegtmeyer P</authors>
            <journal>Molecular and cellular biology</journal>
            <issue>4</issue>
            <page>2157-65</page>
            <year>1995</year>
        </reference>
        <reference>
            <referenceId>24583792</referenceId>
            <title>Phase I dendritic cell p53 peptide vaccine for head and neck cancer.</title>
            <authors>Schuler P, Harasymczuk M, Visus C, Deleo A, Trivedi S, Lei Y, Argiris A, Gooding W, Butterfield L, Whiteside T, Ferris R</authors>
            <journal>Clinical cancer research : an official journal of the American Association for Cancer Research</journal>
            <issue>9</issue>
            <page>2433-44</page>
            <year>2014</year>
        </reference>
        <reference>
            <referenceId>20637128</referenceId>
            <title>Relationship between EGFR expression, copy number and mutation in lung adenocarcinomas.</title>
            <authors>Liang Z, Zhang J, Zeng X, Gao J, Wu S, Liu T</authors>
            <journal>BMC cancer</journal>
            <issue></issue>
            <page>376</page>
            <year>2010</year>
        </reference>
        <reference>
            <referenceId>15329413</referenceId>
            <title>EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.</title>
            <authors>Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H</authors>
            <journal>Proceedings of the National Academy of Sciences of the United States of America</journal>
            <issue>36</issue>
            <page>13306-11</page>
            <year>2004</year>
        </reference>
        <reference>
            <referenceId>23444212</referenceId>
            <title>Notch pathway activity identifies cells with cancer stem cell-like properties and correlates with worse survival in lung adenocarcinoma.</title>
            <authors>Hassan K, Wang L, Korkaya H, Chen G, Maillard I, Beer D, Kalemkerian G, Wicha M</authors>
            <journal>Clinical cancer research : an official journal of the American Association for Cancer Research</journal>
            <issue>8</issue>
            <page>1972-80</page>
            <year>2013</year>
        </reference>
        <reference>
            <referenceId>15472075</referenceId>
            <title>Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.</title>
            <authors>Weng A, Ferrando A, Lee W, Morris J, Silverman L, Sanchez-Irizarry C, Blacklow S, Look A, Aster J</authors>
            <journal>Science (New York, N.Y.)</journal>
            <issue>5694</issue>
            <page>269-71</page>
            <year>2004</year>
        </reference>
        <reference>
            <referenceId>11992543</referenceId>
            <title>Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines.</title>
            <authors>Bancroft C, Chen Z, Yeh J, Sunwoo J, Yeh N, Jackson S, Jackson C, Van Waes C</authors>
            <journal>International journal of cancer. Journal international du cancer</journal>
            <issue>4</issue>
            <page>538-48</page>
            <year>2002</year>
        </reference>
        <reference>
            <referenceId>27039821</referenceId>
            <title>Prevalence and Clinical Profile of EGFR Mutation In Non- Small-Cell Lung Carcinoma Patients in Southwest China.</title>
            <authors>Zhou J, Song X, He H, Zhou Y, Lu X, Ying B</authors>
            <journal>Asian Pacific journal of cancer prevention : APJCP</journal>
            <issue>3</issue>
            <page>965-71</page>
            <year>2016</year>
        </reference>
        <reference>
            <referenceId>23630207</referenceId>
            <title>Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer.</title>
            <authors>Vignot S, Frampton G, Soria J, Yelensky R, Commo F, Brambilla C, Palmer G, Moro-Sibilot D, Ross J, Cronin M, André F, Stephens P, Lazar V, Miller V, Brambilla E</authors>
            <journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal>
            <issue>17</issue>
            <page>2167-72</page>
            <year>2013</year>
        </reference>
        <reference>
            <referenceId>26358312</referenceId>
            <title>Different mutation profiles and clinical characteristics among Hispanic patients with non-small cell lung cancer could explain the "Hispanic paradox".</title>
            <authors>Arrieta O, Ramírez-Tirado L, Báez-Saldaña R, Peña-Curiel O, Soca-Chafre G, Macedo-Perez E</authors>
            <journal>Lung cancer (Amsterdam, Netherlands)</journal>
            <issue></issue>
            <page></page>
            <year>2015</year>
        </reference>
        <reference>
            <referenceId>15118073</referenceId>
            <title>Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.</title>
            <authors>Lynch T, Bell D, Sordella R, Gurubhagavatula S, Okimoto R, Brannigan B, Harris P, Haserlat S, Supko J, Haluska F, Louis D, Christiani D, Settleman J, Haber D</authors>
            <journal>The New England journal of medicine</journal>
            <issue>21</issue>
            <page>2129-39</page>
            <year>2004</year>
        </reference>
        <reference>
            <referenceId>18802452</referenceId>
            <title>Recent advances in p53 research: an interdisciplinary perspective.</title>
            <authors>Olivier M, Petitjean A, Marcel V, Pétré A, Mounawar M, Plymoth A, de Fromentel C, Hainaut P</authors>
            <journal>Cancer gene therapy</journal>
            <issue>1</issue>
            <page>1-12</page>
            <year>2009</year>
        </reference>
        <reference>
            <referenceId>19692684</referenceId>
            <title>Screening for epidermal growth factor receptor mutations in lung cancer.</title>
            <authors>Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzalez-Larriba J, Paz-Ares L, Bover I, Garcia-Campelo R, Moreno M, Catot S, Rolfo C, Reguart N, Palmero R, Sánchez J, Bastus R, Mayo C, Bertran-Alamillo J, Molina M, Sanchez J, Taron M</authors>
            <journal>The New England journal of medicine</journal>
            <issue>10</issue>
            <page>958-67</page>
            <year>2009</year>
        </reference>
        <reference>
            <referenceId>24509876</referenceId>
            <title>Opposing role of Notch1 and Notch2 in a Kras(G12D)-driven murine non-small cell lung cancer model.</title>
            <authors>Baumgart A, Mazur P, Anton M, Rudelius M, Schwamborn K, Feuchtinger A, Behnke K, Walch A, Braren R, Peschel C, Duyster J, Siveke J, Dechow T</authors>
            <journal>Oncogene</journal>
            <issue></issue>
            <page></page>
            <year>2014</year>
        </reference>
        <reference>
            <referenceId>25758253</referenceId>
            <title>p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer.</title>
            <authors>Tentler J, Ionkina A, Tan A, Newton T, Pitts T, Glogowska M, Kabos P, Sartorius C, Sullivan K, Espinosa J, Eckhardt S, Diamond J</authors>
            <journal>Molecular cancer therapeutics</journal>
            <issue>5</issue>
            <page>1117-29</page>
            <year>2015</year>
        </reference>
        <reference>
            <referenceId>26400330</referenceId>
            <title>Correlation of EGFR gene amplification with invasion and metastasis of non-small cell lung cancer.</title>
            <authors>Jia X, Li J, Zhao H, Liu J, Liu J</authors>
            <journal>Genetics and molecular research : GMR</journal>
            <issue>3</issue>
            <page>11006-12</page>
            <year>2015</year>
        </reference>
        <reference>
            <referenceId>23934203</referenceId>
            <title>Detection of EGFR gene mutations in non-small cell lung cancer: lessons from a single-institution routine analysis of 1,403 tumor samples.</title>
            <authors>Vallee A, Sagan C, Le Loupp A, Bach K, Dejoie T, Denis M</authors>
            <journal>International journal of oncology</journal>
            <issue>4</issue>
            <page>1045-51</page>
            <year>2013</year>
        </reference>
        <reference>
            <referenceId>14576853</referenceId>
            <title>The role of p53 in chemosensitivity and radiosensitivity.</title>
            <authors>El-Deiry W</authors>
            <journal>Oncogene</journal>
            <issue>47</issue>
            <page>7486-95</page>
            <year>2003</year>
        </reference>
        <reference>
            <referenceId>26051236</referenceId>
            <title>Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.</title>
            <authors>Yang J, Sequist L, Geater S, Tsai C, Mok T, Schuler M, Yamamoto N, Yu C, Ou S, Zhou C, Massey D, Zazulina V, Wu Y</authors>
            <journal>The Lancet. Oncology</journal>
            <issue>7</issue>
            <page>830-8</page>
            <year>2015</year>
        </reference>
        <reference>
            <referenceId>23135908</referenceId>
            <title>Cisplatin selects for multidrug-resistant CD133+ cells in lung adenocarcinoma by activating Notch signaling.</title>
            <authors>Liu Y, Yang C, Huang M, Yeh C, Wu A, Lee Y, Lai T, Lee C, Hsiao Y, Lu J, Shen C, Lu P, Hsiao M</authors>
            <journal>Cancer research</journal>
            <issue>1</issue>
            <page>406-16</page>
            <year>2013</year>
        </reference>
        <reference>
            <referenceId>23868008</referenceId>
            <title>Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a ?-secretase inhibitor, in a preclinical colorectal explant model.</title>
            <authors>Arcaroli J, Quackenbush K, Purkey A, Powell R, Pitts T, Bagby S, Tan A, Cross B, McPhillips K, Song E, Tai W, Winn R, Bikkavilli K, Vanscoyk M, Eckhardt S, Messersmith W</authors>
            <journal>British journal of cancer</journal>
            <issue>3</issue>
            <page>667-75</page>
            <year>2013</year>
        </reference>
        <reference>
            <referenceId>21761334</referenceId>
            <title>Functional significance of Aurora kinase A regulatory interactions with p53-ERα complex in human breast cancer cells.</title>
            <authors>Katayama H, Sen S</authors>
            <journal>Hormones &amp; cancer</journal>
            <issue>2</issue>
            <page>117-24</page>
            <year>2011</year>
        </reference>
        <reference>
            <referenceId>21331359</referenceId>
            <title>TP53 mutations in nonsmall cell lung cancer.</title>
            <authors>Mogi A, Kuwano H</authors>
            <journal>Journal of biomedicine &amp; biotechnology</journal>
            <issue></issue>
            <page>583929</page>
            <year>2011</year>
        </reference>
        <reference>
            <referenceId>19404848</referenceId>
            <title>Immunohistochemical expression of EGFR in colorectal carcinoma correlates with high but not low level gene amplification, as demonstrated by CISH.</title>
            <authors>Hemmings C, Broomfield A, Bean E, Whitehead M, Yip D</authors>
            <journal>Pathology</journal>
            <issue>4</issue>
            <page>356-60</page>
            <year>2009</year>
        </reference>
        <reference>
            <referenceId>21767894</referenceId>
            <title>The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor.</title>
            <authors>Kobayashi N, Toyooka S, Soh J, Yamamoto H, Dote H, Kawasaki K, Otani H, Kubo T, Jida M, Ueno T, Ando M, Ogino A, Kiura K, Miyoshi S</authors>
            <journal>Lung cancer (Amsterdam, Netherlands)</journal>
            <issue>2</issue>
            <page>161-6</page>
            <year>2012</year>
        </reference>
        <reference>
            <referenceId>26045340</referenceId>
            <title>Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.</title>
            <authors>Thatcher N, Hirsch F, Luft A, Szczesna A, Ciuleanu T, Dediu M, Ramlau R, Galiulin R, Bálint B, Losonczy G, Kazarnowicz A, Park K, Schumann C, Reck M, Depenbrock H, Nanda S, Kruljac-Letunic A, Kurek R, Paz-Ares L, Socinski M</authors>
            <journal>The Lancet. Oncology</journal>
            <issue>7</issue>
            <page>763-74</page>
            <year>2015</year>
        </reference>
        <reference>
            <referenceId>21803744</referenceId>
            <title>Activated Notch1 induces lung adenomas in mice and cooperates with Myc in the generation of lung adenocarcinoma.</title>
            <authors>Allen T, Rodriguez E, Jones K, Bishop J</authors>
            <journal>Cancer research</journal>
            <issue>18</issue>
            <page>6010-8</page>
            <year>2011</year>
        </reference>
        <reference>
            <referenceId>22006338</referenceId>
            <title>Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma.</title>
            <authors>Wang N, Sanborn Z, Arnett K, Bayston L, Liao W, Proby C, Leigh I, Collisson E, Gordon P, Jakkula L, Pennypacker S, Zou Y, Sharma M, North J, Vemula S, Mauro T, Neuhaus I, Leboit P, Hur J, Park K, Huh N, Kwok P, Arron S, Massion P, Bale A, Haussler D, Cleaver J, Gray J, Spellman P, South A, Aster J, Blacklow S, Cho R</authors>
            <journal>Proceedings of the National Academy of Sciences of the United States of America</journal>
            <issue>43</issue>
            <page>17761-6</page>
            <year>2011</year>
        </reference>
        <reference>
            <referenceId>21220471</referenceId>
            <title>Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors.</title>
            <authors>Jänne P, Boss D, Camidge D, Britten C, Engelman J, Garon E, Guo F, Wong S, Liang J, Letrent S, Millham R, Taylor I, Eckhardt S, Schellens J</authors>
            <journal>Clinical cancer research : an official journal of the American Association for Cancer Research</journal>
            <issue>5</issue>
            <page>1131-9</page>
            <year>2011</year>
        </reference>
        <reference>
            <referenceId>27357628</referenceId>
            <title>Safety and Efficacy in Advanced Solid Tumors of a Targeted Nanocomplex Carrying the p53 Gene Used in Combination with Docetaxel: A Phase 1b Study.</title>
            <authors>Pirollo K, Nemunaitis J, Leung P, Nunan R, Adams J, Chang E</authors>
            <journal>Molecular therapy : the journal of the American Society of Gene Therapy</journal>
            <issue></issue>
            <page></page>
            <year>2016</year>
        </reference>
        <reference>
            <referenceId>22207554</referenceId>
            <title>High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients.</title>
            <authors>Park S, Choi Y, Sung C, An J, Seo J, Ahn M, Ahn J, Park K, Shin Y, Erkin O, Song K, Kim J, Shim Y, Han J</authors>
            <journal>Histology and histopathology</journal>
            <issue>2</issue>
            <page>197-207</page>
            <year>2012</year>
        </reference>
        <reference>
            <referenceId>23943799</referenceId>
            <title>Notch1 is required for Kras-induced lung adenocarcinoma and controls tumor cell survival via p53.</title>
            <authors>Licciulli S, Avila J, Hanlon L, Troutman S, Cesaroni M, Kota S, Keith B, Simon M, Puré E, Radtke F, Capobianco A, Kissil J</authors>
            <journal>Cancer research</journal>
            <issue>19</issue>
            <page>5974-84</page>
            <year>2013</year>
        </reference>
        <reference>
            <referenceId>24277854</referenceId>
            <title>Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974.</title>
            <authors>Liu J, Pan S, Hsieh M, Ng N, Sun F, Wang T, Kasibhatla S, Schuller A, Li A, Cheng D, Li J, Tompkins C, Pferdekamper A, Steffy A, Cheng J, Kowal C, Phung V, Guo G, Wang Y, Graham M, Flynn S, Brenner J, Li C, Villarroel M, Schultz P, Wu X, McNamara P, Sellers W, Petruzzelli L, Boral A, Seidel H, McLaughlin M, Che J, Carey T, Vanasse G, Harris J</authors>
            <journal>Proceedings of the National Academy of Sciences of the United States of America</journal>
            <issue>50</issue>
            <page>20224-9</page>
            <year>2013</year>
        </reference>
        <reference>
            <referenceId>21233402</referenceId>
            <title>Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.</title>
            <authors>Rosell R, Molina M, Costa C, Simonetti S, Gimenez-Capitan A, Bertran-Alamillo J, Mayo C, Moran T, Mendez P, Cardenal F, Isla D, Provencio M, Cobo M, Insa A, Garcia-Campelo R, Reguart N, Majem M, Viteri S, Carcereny E, Porta R, Massuti B, Queralt C, de Aguirre I, Sanchez J, Sanchez-Ronco M, Mate J, Ariza A, Benlloch S, Sanchez J, Bivona T, Sawyers C, Taron M</authors>
            <journal>Clinical cancer research : an official journal of the American Association for Cancer Research</journal>
            <issue>5</issue>
            <page>1160-8</page>
            <year>2011</year>
        </reference>
        <reference>
            <referenceId>15118125</referenceId>
            <title>EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.</title>
            <authors>Paez J, Jänne P, Lee J, Tracy S, Greulich H, Gabriel S, Herman P, Kaye F, Lindeman N, Boggon T, Naoki K, Sasaki H, Fujii Y, Eck M, Sellers W, Johnson B, Meyerson M</authors>
            <journal>Science (New York, N.Y.)</journal>
            <issue>5676</issue>
            <page>1497-500</page>
            <year>2004</year>
        </reference>
        <reference>
            <referenceId>27117272</referenceId>
            <title>In vivo Wnt pathway inhibition of human squamous cell carcinoma growth and metastasis in the chick chorioallantoic model.</title>
            <authors>Rudy S, Brenner J, Harris J, Liu J, Che J, Scott M, Owen J, Komarck C, Graham M, Bellile E, Bradford C, Prince M, Carey T</authors>
            <journal>Journal of otolaryngology - head &amp; neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale</journal>
            <issue></issue>
            <page>26</page>
            <year>2016</year>
        </reference>
        <reference>
            <referenceId>1683921</referenceId>
            <title>p53 germline mutations in Li-Fraumeni syndrome.</title>
            <authors>Santibáñez-Koref M, Birch J, Hartley A, Jones P, Craft A, Eden T, Crowther D, Kelsey A, Harris M</authors>
            <journal>Lancet</journal>
            <issue>8781</issue>
            <page>1490-1</page>
            <year>1991</year>
        </reference>
        <reference>
            <referenceId>11400116</referenceId>
            <title>Heterogeneous distribution of P53 immunoreactivity in human lung adenocarcinoma correlates with MDM2 protein expression, rather than with P53 gene mutation.</title>
            <authors>Koga T, Hashimoto S, Sugio K, Yoshino I, Nakagawa K, Yonemitsu Y, Sugimachi K, Sueishi K</authors>
            <journal>International journal of cancer. Journal international du cancer</journal>
            <issue>4</issue>
            <page>232-9</page>
            <year>2001</year>
        </reference>
        <reference>
            <referenceId>23314677</referenceId>
            <title>Concomitant high gene copy number and protein overexpression of IGF1R and EGFR negatively affect disease-free survival of surgically resected non-small-cell-lung cancer patients.</title>
            <authors>Ludovini V, Flacco A, Bianconi F, Ragusa M, Vannucci J, Bellezza G, Chiari R, Minotti V, Pistola L, Tofanetti F, Siggillino A, Baldelli E, Sidoni A, Daddi N, Puma F, Varella-Garcia M, Crinò L</authors>
            <journal>Cancer chemotherapy and pharmacology</journal>
            <issue>3</issue>
            <page>671-80</page>
            <year>2013</year>
        </reference>
        <reference>
            <referenceId>17664472</referenceId>
            <title>Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab.</title>
            <authors>Sartore-Bianchi A, Moroni M, Veronese S, Carnaghi C, Bajetta E, Luppi G, Sobrero A, Barone C, Cascinu S, Colucci G, Cortesi E, Nichelatti M, Gambacorta M, Siena S</authors>
            <journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal>
            <issue>22</issue>
            <page>3238-45</page>
            <year>2007</year>
        </reference>
        <reference>
            <referenceId>20007775</referenceId>
            <title>Alterations of the Notch pathway in lung cancer.</title>
            <authors>Westhoff B, Colaluca I, D'Ario G, Donzelli M, Tosoni D, Volorio S, Pelosi G, Spaggiari L, Mazzarol G, Viale G, Pece S, Di Fiore P</authors>
            <journal>Proceedings of the National Academy of Sciences of the United States of America</journal>
            <issue>52</issue>
            <page>22293-8</page>
            <year>2009</year>
        </reference>
        <reference>
            <referenceId>19714203</referenceId>
            <title>Hierarchical modeling of activation mechanisms in the ABL and EGFR kinase domains: thermodynamic and mechanistic catalysts of kinase activation by cancer mutations.</title>
            <authors>Dixit A, Verkhivker G</authors>
            <journal>PLoS computational biology</journal>
            <issue>8</issue>
            <page>e1000487</page>
            <year>2009</year>
        </reference>
        <reference>
            <referenceId>22309842</referenceId>
            <title>Therapeutic approaches to modulating Notch signaling: current challenges and future prospects.</title>
            <authors>Groth C, Fortini M</authors>
            <journal>Seminars in cell &amp; developmental biology</journal>
            <issue>4</issue>
            <page>465-72</page>
            <year>2012</year>
        </reference>
        <reference>
            <referenceId>23609015</referenceId>
            <title>Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors.</title>
            <authors>Senzer N, Nemunaitis J, Nemunaitis D, Bedell C, Edelman G, Barve M, Nunan R, Pirollo K, Rait A, Chang E</authors>
            <journal>Molecular therapy : the journal of the American Society of Gene Therapy</journal>
            <issue>5</issue>
            <page>1096-103</page>
            <year>2013</year>
        </reference>
        <reference>
            <referenceId>15625370</referenceId>
            <title>Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer.</title>
            <authors>Wang Y, Lin R, Tan Y, Chen J, Chen C, Wang Y</authors>
            <journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal>
            <issue>1</issue>
            <page>154-64</page>
            <year>2005</year>
        </reference>
        <reference>
            <referenceId>9039259</referenceId>
            <title>p53, the cellular gatekeeper for growth and division.</title>
            <authors>Levine A</authors>
            <journal>Cell</journal>
            <issue>3</issue>
            <page>323-31</page>
            <year>1997</year>
        </reference>
        <reference>
            <referenceId>27616574</referenceId>
            <title>Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells.</title>
            <authors>Wang Y, Shen A, Sun J, Wang X, Liu H, Zhang M, Chen D, Xiong B, Shen J, Geng M, Zheng M, Ding J</authors>
            <journal>Acta pharmacologica Sinica</journal>
            <issue>12</issue>
            <page>1587-1596</page>
            <year>2016</year>
        </reference>
        <reference>
            <referenceId>24396405</referenceId>
            <title>mRNA expression of CK19, EGFR and LUNX in patients with lung cancer micrometastasis.</title>
            <authors>Zhang X, Xie J, Yu C, Yan L, Yang Z</authors>
            <journal>Experimental and therapeutic medicine</journal>
            <issue>2</issue>
            <page>360-364</page>
            <year>2014</year>
        </reference>
        <reference>
            <referenceId>23238037</referenceId>
            <title>Frequent intratumoral heterogeneity of EGFR gene copy gain in non-small cell lung cancer.</title>
            <authors>Grob T, Hoenig T, Clauditz T, Atanackovic D, Koenig A, Vashist Y, Klose H, Simon R, Pantel K, Izbicki J, Bokemeyer C, Sauter G, Wilczak W</authors>
            <journal>Lung cancer (Amsterdam, Netherlands)</journal>
            <issue>3</issue>
            <page>221-7</page>
            <year>2013</year>
        </reference>
        <reference>
            <referenceId>26992209</referenceId>
            <title>Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers.</title>
            <authors>Lee B, Lee T, Lee S, Choi Y, Han J</authors>
            <journal>Oncotarget</journal>
            <issue></issue>
            <page></page>
            <year>2016</year>
        </reference>
        <reference>
            <referenceId>23816960</referenceId>
            <title>Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.</title>
            <authors>Sequist L, Yang J, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater S, Orlov S, Tsai C, Boyer M, Su W, Bennouna J, Kato T, Gorbunova V, Lee K, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M</authors>
            <journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal>
            <issue>27</issue>
            <page>3327-34</page>
            <year>2013</year>
        </reference>
        <reference>
            <referenceId>IASLC 2015, Abstract 1406</referenceId>
            <title>AZD9291 in Pre-Treated T790M Positive Advanced NSCLC: AURA2 Phase II Study (Now Available</title>
            <authors>Mitsudomi T, Tsai C, Shepherd F et al.</authors>
            <journal>J Thor Oncol</journal>
            <issue></issue>
            <page></page>
            <year>2015</year>
        </reference>
        <reference>
            <referenceId>25668228</referenceId>
            <title>EGFR T790M resistance mutation in non small-cell lung carcinoma.</title>
            <authors>Denis M, Vallée A, Théoleyre S</authors>
            <journal>Clinica chimica acta; international journal of clinical chemistry</journal>
            <issue></issue>
            <page>81-5</page>
            <year>2015</year>
        </reference>
        <reference>
            <referenceId>24300726</referenceId>
            <title>EGFR gene copy number alterations are not a useful screening tool for predicting EGFR mutation status in lung adenocarcinoma.</title>
            <authors>Russell P, Yu Y, Do H, Clay T, Moore M, Wright G, Conron M, Wainer Z, Dobrovic A, McLachlan S</authors>
            <journal>Pathology</journal>
            <issue>1</issue>
            <page>32-6</page>
            <year>2014</year>
        </reference>
        <reference>
            <referenceId>23955083</referenceId>
            <title>p53 deficiency enhances mitotic arrest and slippage induced by pharmacological inhibition of Aurora kinases.</title>
            <authors>Marxer M, Ma H, Man W, Poon R</authors>
            <journal>Oncogene</journal>
            <issue>27</issue>
            <page>3550-60</page>
            <year>2014</year>
        </reference>
        <reference>
            <referenceId>25884692</referenceId>
            <title>Prognostic role of serum p53 antibodies in lung cancer.</title>
            <authors>Mattioni M, Soddu S, Prodosmo A, Visca P, Conti S, Alessandrini G, Facciolo F, Strigari L</authors>
            <journal>BMC cancer</journal>
            <issue></issue>
            <page>148</page>
            <year>2015</year>
        </reference>
        <reference>
            <referenceId>20479403</referenceId>
            <title>Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.</title>
            <authors>Sequist L, Besse B, Lynch T, Miller V, Wong K, Gitlitz B, Eaton K, Zacharchuk C, Freyman A, Powell C, Ananthakrishnan R, Quinn S, Soria J</authors>
            <journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal>
            <issue>18</issue>
            <page>3076-83</page>
            <year>2010</year>
        </reference>
        <reference>
            <referenceId>24323028</referenceId>
            <title>Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients.</title>
            <authors>Kim Y, Hammerman P, Kim J, Yoon J, Lee Y, Sun J, Wilkerson M, Pedamallu C, Cibulskis K, Yoo Y, Lawrence M, Stojanov P, Carter S, McKenna A, Stewart C, Sivachenko A, Oh I, Kim H, Choi Y, Kim K, Shim Y, Kim K, Song S, Na K, Choi Y, Hayes D, Kim J, Cho S, Kim Y, Ahn J, Ahn M, Getz G, Meyerson M, Park K</authors>
            <journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal>
            <issue>2</issue>
            <page>121-8</page>
            <year>2014</year>
        </reference>
        <reference>
            <referenceId>12826609</referenceId>
            <title>Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis.</title>
            <authors>Kato S, Han S, Liu W, Otsuka K, Shibata H, Kanamaru R, Ishioka C</authors>
            <journal>Proceedings of the National Academy of Sciences of the United States of America</journal>
            <issue>14</issue>
            <page>8424-9</page>
            <year>2003</year>
        </reference>
        <reference>
            <referenceId>25439691</referenceId>
            <title>Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial.</title>
            <authors>Ramalingam S, Jänne P, Mok T, O'Byrne K, Boyer M, Von Pawel J, Pluzanski A, Shtivelband M, Docampo L, Bennouna J, Zhang H, Liang J, Doherty J, Taylor I, Mather C, Goldberg Z, O'Connell J, Paz-Ares L</authors>
            <journal>The Lancet. Oncology</journal>
            <issue>12</issue>
            <page>1369-78</page>
            <year>2014</year>
        </reference>
        <reference>
            <referenceId>18948947</referenceId>
            <title>Somatic mutations affect key pathways in lung adenocarcinoma.</title>
            <authors>Ding L, Getz G, Wheeler D, Mardis E, McLellan M, Cibulskis K, Sougnez C, Greulich H, Muzny D, Morgan M, Fulton L, Fulton R, Zhang Q, Wendl M, Lawrence M, Larson D, Chen K, Dooling D, Sabo A, Hawes A, Shen H, Jhangiani S, Lewis L, Hall O, Zhu Y, Mathew T, Ren Y, Yao J, Scherer S, Clerc K, Metcalf G, Ng B, Milosavljevic A, Gonzalez-Garay M, Osborne J, Meyer R, Shi X, Tang Y, Koboldt D, Lin L, Abbott R, Miner T, Pohl C, Fewell G, Haipek C, Schmidt H, Dunford-Shore B, Kraja A, Crosby S, Sawyer C, Vickery T, Sander S, Robinson J, Winckler W, Baldwin J, Chirieac L, Dutt A, Fennell T, Hanna M, Johnson B, Onofrio R, Thomas R, Tonon G, Weir B, Zhao X, Ziaugra L, Zody M, Giordano T, Orringer M, Roth J, Spitz M, Wistuba I, Ozenberger B, Good P, Chang A, Beer D, Watson M, Ladanyi M, Broderick S, Yoshizawa A, Travis W, Pao W, Province M, Weinstock G, Varmus H, Gabriel S, Lander E, Gibbs R, Meyerson M, Wilson R</authors>
            <journal>Nature</journal>
            <issue>7216</issue>
            <page>1069-75</page>
            <year>2008</year>
        </reference>
        <reference>
            <referenceId>22806877</referenceId>
            <title>Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer.</title>
            <authors>Shimamura T, Perera S, Foley K, Sang J, Rodig S, Inoue T, Chen L, Li D, Carretero J, Li Y, Sinha P, Carey C, Borgman C, Jimenez J, Meyerson M, Ying W, Barsoum J, Wong K, Shapiro G</authors>
            <journal>Clinical cancer research : an official journal of the American Association for Cancer Research</journal>
            <issue>18</issue>
            <page>4973-85</page>
            <year>2012</year>
        </reference>
        <reference>
            <referenceId>22173954</referenceId>
            <title>Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells.</title>
            <authors>Xie M, Zhang L, He C, Xu F, Liu J, Hu Z, Zhao L, Tian Y</authors>
            <journal>Journal of cellular biochemistry</journal>
            <issue>5</issue>
            <page>1501-13</page>
            <year>2012</year>
        </reference>
        <reference>
            <referenceId>15897464</referenceId>
            <title>Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.</title>
            <authors>Kwak E, Sordella R, Bell D, Godin-Heymann N, Okimoto R, Brannigan B, Harris P, Driscoll D, Fidias P, Lynch T, Rabindran S, McGinnis J, Wissner A, Sharma S, Isselbacher K, Settleman J, Haber D</authors>
            <journal>Proceedings of the National Academy of Sciences of the United States of America</journal>
            <issue>21</issue>
            <page>7665-70</page>
            <year>2005</year>
        </reference>
        <reference>
            <referenceId>22611192</referenceId>
            <title>Aurora B kinase phosphorylates and instigates degradation of p53.</title>
            <authors>Gully C, Velazquez-Torres G, Shin J, Fuentes-Mattei E, Wang E, Carlock C, Chen J, Rothenberg D, Adams H, Choi H, Guma S, Phan L, Chou P, Su C, Zhang F, Chen J, Yang T, Yeung S, Lee M</authors>
            <journal>Proceedings of the National Academy of Sciences of the United States of America</journal>
            <issue>24</issue>
            <page>E1513-22</page>
            <year>2012</year>
        </reference>
        <reference>
            <referenceId>21694725</referenceId>
            <title>EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer.</title>
            <authors>Ålgars A, Lintunen M, Carpén O, Ristamäki R, Sundström J</authors>
            <journal>British journal of cancer</journal>
            <issue>2</issue>
            <page>255-62</page>
            <year>2011</year>
        </reference>
        <reference>
            <referenceId>24101933</referenceId>
            <title>Neuroendocrine differentiation in acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitor.</title>
            <authors>Chang Y, Kim S, Choi Y, So K, Rho J, Kim W, Lee J, Chung J, Choi C</authors>
            <journal>Tuberculosis and respiratory diseases</journal>
            <issue>3</issue>
            <page>95-103</page>
            <year>2013</year>
        </reference>
        <reference>
            <referenceId>23312887</referenceId>
            <title>Transformation to "high grade" neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma.</title>
            <authors>Popat S, Wotherspoon A, Nutting C, Gonzalez D, Nicholson A, O'Brien M</authors>
            <journal>Lung cancer (Amsterdam, Netherlands)</journal>
            <issue>1</issue>
            <page>1-4</page>
            <year>2013</year>
        </reference>
        <reference>
            <referenceId>25728526</referenceId>
            <title>Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study.</title>
            <authors>Melichar B, Adenis A, Lockhart A, Bennouna J, Dees E, Kayaleh O, Obermannova R, DeMichele A, Zatloukal P, Zhang B, Ullmann C, Schusterbauer C</authors>
            <journal>The Lancet. Oncology</journal>
            <issue></issue>
            <page></page>
            <year>2015</year>
        </reference>
        <reference>
            <referenceId>ASCO 2015, Abstract 2533</referenceId>
            <title>First-in-human study of LY3039478, a Notch signaling inhibitor in advanced or metastatic cancer.</title>
            <authors>Massard C, Azaro A, Tourneau CL, et al.</authors>
            <journal>J Clin Oncol</journal>
            <issue></issue>
            <page>Abstract 2533</page>
            <year>2015</year>
        </reference>
        <reference>
            <referenceId>27738317</referenceId>
            <title>The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis.</title>
            <authors>Zhang Y, Yuan J, Wang K, Fu X, Han X, Threapleton D, Yang Z, Mao C, Tang J</authors>
            <journal>Oncotarget</journal>
            <issue>48</issue>
            <page>78985-78993</page>
            <year>2016</year>
        </reference>
        <reference>
            <referenceId>21760960</referenceId>
            <title>High-level expression of wild-type p53 in melanoma cells is frequently associated with inactivity in p53 reporter gene assays.</title>
            <authors>Houben R, Hesbacher S, Schmid C, Kauczok C, Flohr U, Haferkamp S, Müller C, Schrama D, Wischhusen J, Becker J</authors>
            <journal>PloS one</journal>
            <issue>7</issue>
            <page>e22096</page>
            <year>2011</year>
        </reference>
        <reference>
            <referenceId>15998906</referenceId>
            <title>Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.</title>
            <authors>Hirsch F, Varella-Garcia M, McCoy J, West H, Xavier A, Gumerlock P, Bunn P, Franklin W, Crowley J, Gandara D</authors>
            <journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal>
            <issue>28</issue>
            <page>6838-45</page>
            <year>2005</year>
        </reference>
        <reference>
            <referenceId>21541192</referenceId>
            <title>Immunological and clinical effects of vaccines targeting p53-overexpressing malignancies.</title>
            <authors>Vermeij R, Leffers N, van der Burg S, Melief C, Daemen T, Nijman H</authors>
            <journal>Journal of biomedicine &amp; biotechnology</journal>
            <issue></issue>
            <page>702146</page>
            <year>2011</year>
        </reference>
        <reference>
            <referenceId>25398437</referenceId>
            <title>Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells.</title>
            <authors>Vilgelm A, Pawlikowski J, Liu Y, Hawkins O, Davis T, Smith J, Weller K, Horton L, McClain C, Ayers G, Turner D, Essaka D, Stewart C, Sosman J, Kelley M, Ecsedy J, Johnston J, Richmond A</authors>
            <journal>Cancer research</journal>
            <issue>1</issue>
            <page>181-93</page>
            <year>2015</year>
        </reference>
        <reference>
            <referenceId>21531810</referenceId>
            <title>Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.</title>
            <authors>Wu J, Yu C, Chang Y, Yang C, Shih J, Yang P</authors>
            <journal>Clinical cancer research : an official journal of the American Association for Cancer Research</journal>
            <issue>11</issue>
            <page>3812-21</page>
            <year>2011</year>
        </reference>
        <reference>
            <referenceId>26285137</referenceId>
            <title>The Efficacy of Synchronous Combination of Chemotherapy and EGFR TKIs for the First-Line Treatment of NSCLC: A Systematic Analysis.</title>
            <authors>Yan H, Li H, Li Q, Zhao P, Wang W, Cao B</authors>
            <journal>PloS one</journal>
            <issue>8</issue>
            <page>e0135829</page>
            <year>2015</year>
        </reference>
        <reference>
            <referenceId>15269313</referenceId>
            <title>Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.</title>
            <authors>Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E</authors>
            <journal>The New England journal of medicine</journal>
            <issue>4</issue>
            <page>337-45</page>
            <year>2004</year>
        </reference>
        <reference>
            <referenceId>1978757</referenceId>
            <title>Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.</title>
            <authors>Malkin D, Li F, Strong L, Fraumeni J, Nelson C, Kim D, Kassel J, Gryka M, Bischoff F, Tainsky M</authors>
            <journal>Science (New York, N.Y.)</journal>
            <issue>4985</issue>
            <page>1233-8</page>
            <year>1990</year>
        </reference>
        <reference>
            <referenceId>21562564</referenceId>
            <title>A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia.</title>
            <authors>Klinakis A, Lobry C, Abdel-Wahab O, Oh P, Haeno H, Buonamici S, van De Walle I, Cathelin S, Trimarchi T, Araldi E, Liu C, Ibrahim S, Beran M, Zavadil J, Efstratiadis A, Taghon T, Michor F, Levine R, Aifantis I</authors>
            <journal>Nature</journal>
            <issue>7346</issue>
            <page>230-3</page>
            <year>2011</year>
        </reference>
        <reference>
            <referenceId>22897982</referenceId>
            <title>EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-analysis.</title>
            <authors>Yang Z, Shen W, Hu X, Zheng D, Wu X, Huang Y, Chen J, Mao C, Tang J</authors>
            <journal>Journal of hematology &amp; oncology</journal>
            <issue></issue>
            <page>52</page>
            <year>2012</year>
        </reference>
        <reference>
            <referenceId>21587084</referenceId>
            <title>Higher dosage of the epidermal growth factor receptor mutant allele in lung adenocarcinoma correlates with younger age, stage IV at presentation, and poorer survival.</title>
            <authors>Oakley G, Chiosea S</authors>
            <journal>Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</journal>
            <issue>8</issue>
            <page>1407-12</page>
            <year>2011</year>
        </reference>
        <reference>
            <referenceId>18784101</referenceId>
            <title>Platinum-based chemotherapy plus cetuximab in head and neck cancer.</title>
            <authors>Vermorken J, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer H, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R</authors>
            <journal>The New England journal of medicine</journal>
            <issue>11</issue>
            <page>1116-27</page>
            <year>2008</year>
        </reference>
        <reference>
            <referenceId>NCCNGuidelines</referenceId>
            <title>NCCN Guidelines® are referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia V.1.2016, Breast Cancer V.1.2016, Central Nervous System Cancers V.1.2015, Gastric Cancer V.3.2015, Non-Small Cell Lung Cancer V.4.2016, Colon Cancer V.2.2016, Rectal Cancer V.1.2016, Melanoma V.2.2016, Neuroendocrine Tumors V.1.2015, Ovarian Cancer V.2.2015, Pancreatic Adenocarcinoma V.1.2016, Prostate Cancer V.2.2016, and Uterine Neoplasms V.2.2016. © 2016 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines® and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org</title>
            <authors>NCCN</authors>
            <journal></journal>
            <issue></issue>
            <page></page>
        </reference>
        <reference>
            <referenceId>21131552</referenceId>
            <title>Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors.</title>
            <authors>Diamond J, Bastos B, Hansen R, Gustafson D, Eckhardt S, Kwak E, Pandya S, Fletcher G, Pitts T, Kulikowski G, Morrow M, Arnott J, Bray M, Sidor C, Messersmith W, Shapiro G</authors>
            <journal>Clinical cancer research : an official journal of the American Association for Cancer Research</journal>
            <issue>4</issue>
            <page>849-60</page>
            <year>2011</year>
        </reference>
        <reference>
            <referenceId>21040950</referenceId>
            <title>Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor/Akt in human lung carcinomas.</title>
            <authors>Dobashi Y, Suzuki S, Kimura M, Matsubara H, Tsubochi H, Imoto I, Ooi A</authors>
            <journal>Human pathology</journal>
            <issue>2</issue>
            <page>214-26</page>
            <year>2011</year>
        </reference>
        <reference>
            <referenceId>23754386</referenceId>
            <title>Effects of oncogenic mutations on the conformational free-energy landscape of EGFR kinase.</title>
            <authors>Sutto L, Gervasio F</authors>
            <journal>Proceedings of the National Academy of Sciences of the United States of America</journal>
            <issue>26</issue>
            <page>10616-21</page>
            <year>2013</year>
        </reference>
        <reference>
            <referenceId>17452677</referenceId>
            <title>Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.</title>
            <authors>Moore M, Goldstein D, Hamm J, Figer A, Hecht J, Gallinger S, Au H, Murawa P, Walde D, Wolff R, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W</authors>
            <journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal>
            <issue>15</issue>
            <page>1960-6</page>
            <year>2007</year>
        </reference>
        <reference>
            <referenceId>18227510</referenceId>
            <title>The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP.</title>
            <authors>Yun C, Mengwasser K, Toms A, Woo M, Greulich H, Wong K, Meyerson M, Eck M</authors>
            <journal>Proceedings of the National Academy of Sciences of the United States of America</journal>
            <issue>6</issue>
            <page>2070-5</page>
            <year>2008</year>
        </reference>
        <reference>
            <referenceId>27198355</referenceId>
            <title>1320_PR: Subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC).</title>
            <authors>Paz-Ares L, Socinski M, Shahidi J, Hozak R, Soldatenkova V, Thatcher N, Hirsch F</authors>
            <journal>Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</journal>
            <issue>4 Suppl</issue>
            <page>S153</page>
            <year>2016</year>
        </reference>
        <reference>
            <referenceId>26729184</referenceId>
            <title>Osimertinib: First Global Approval.</title>
            <authors>Greig S</authors>
            <journal>Drugs</journal>
            <issue>2</issue>
            <page>263-73</page>
            <year>2016</year>
        </reference>
        <reference>
            <referenceId>23011884</referenceId>
            <title>Functional effect of polymorphisms in 15q25 locus on CHRNA5 mRNA, bulky DNA adducts and TP53 mutations.</title>
            <authors>Tekpli X, Landvik N, Skaug V, Gulsvik A, Haugen A, Zienolddiny S</authors>
            <journal>International journal of cancer. Journal international du cancer</journal>
            <issue>8</issue>
            <page>1811-20</page>
            <year>2013</year>
        </reference>
        <reference>
            <referenceId>ASCO 2013, Abstract 8053</referenceId>
            <title>Nimotuzumab plus chemotherapy versus chemotherapy alone in advanced non-small cell lung cancer: A phase II, open-label, multicenter, randomized study.</title>
            <authors>Prabhash K, Babu KG, Vaid AK et al.</authors>
            <journal>J Clin Oncol</journal>
            <issue></issue>
            <page></page>
            <year>2013</year>
        </reference>
        <reference>
            <referenceId>26862733</referenceId>
            <title>The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients.</title>
            <authors>Wu S, Liu Y, Tsai M, Chang Y, Yu C, Yang P, Yang J, Wen Y, Shih J</authors>
            <journal>Oncotarget</journal>
            <issue>11</issue>
            <page>12404-13</page>
            <year>2016</year>
        </reference>
        <reference>
            <referenceId>16204011</referenceId>
            <title>Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.</title>
            <authors>Bell D, Lynch T, Haserlat S, Harris P, Okimoto R, Brannigan B, Sgroi D, Muir B, Riemenschneider M, Iacona R, Krebs A, Johnson D, Giaccone G, Herbst R, Manegold C, Fukuoka M, Kris M, Baselga J, Ochs J, Haber D</authors>
            <journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal>
            <issue>31</issue>
            <page>8081-92</page>
            <year>2005</year>
        </reference>
        <reference>
            <referenceId>27207107</referenceId>
            <title>Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer.</title>
            <authors>Paz-Ares L, Socinski M, Shahidi J, Hozak R, Soldatenkova V, Kurek R, Varella-Garcia M, Thatcher N, Hirsch F</authors>
            <journal>Annals of oncology : official journal of the European Society for Medical Oncology</journal>
            <issue>8</issue>
            <page>1573-9</page>
            <year>2016</year>
        </reference>
        <reference>
            <referenceId>21430269</referenceId>
            <title>Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.</title>
            <authors>Sequist L, Waltman B, Dias-Santagata D, Digumarthy S, Turke A, Fidias P, Bergethon K, Shaw A, Gettinger S, Cosper A, Akhavanfard S, Heist R, Temel J, Christensen J, Wain J, Lynch T, Vernovsky K, Mark E, Lanuti M, Iafrate A, Mino-Kenudson M, Engelman J</authors>
            <journal>Science translational medicine</journal>
            <issue>75</issue>
            <page>75ra26</page>
            <year>2011</year>
        </reference>
        <reference>
            <referenceId>24452282</referenceId>
            <title>Association between epidermal growth factor receptor gene copy number and ERCC1, BRCA1 protein expression in Chinese patients with non-small cell lung cancer.</title>
            <authors>Zhang Y, Yang H, Qiu Y, Deng Q, Liu J, Zhao M, He P, Mo M, Zou X, He J</authors>
            <journal>Medical oncology (Northwood, London, England)</journal>
            <issue>3</issue>
            <page>803</page>
            <year>2014</year>
        </reference>
        <reference>
            <referenceId>18337605</referenceId>
            <title>EGFR antagonists in cancer treatment.</title>
            <authors>Ciardiello F, Tortora G</authors>
            <journal>The New England journal of medicine</journal>
            <issue>11</issue>
            <page>1160-74</page>
            <year>2008</year>
        </reference>
        <reference>
            <referenceId>27343443</referenceId>
            <title>Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.</title>
            <authors>Schrock A, Frampton G, Suh J, Chalmers Z, Rosenzweig M, Erlich R, Halmos B, Goldman J, Forde P, Leuenberger K, Peled N, Kalemkerian G, Ross J, Stephens P, Miller V, Ali S, Ou S</authors>
            <journal>Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</journal>
            <issue>9</issue>
            <page>1493-502</page>
            <year>2016</year>
        </reference>
        <reference>
            <referenceId>16014882</referenceId>
            <title>Erlotinib in previously treated non-small-cell lung cancer.</title>
            <authors>Shepherd F, Rodrigues Pereira J, Ciuleanu T, Tan E, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L</authors>
            <journal>The New England journal of medicine</journal>
            <issue>2</issue>
            <page>123-32</page>
            <year>2005</year>
        </reference>
        <reference>
            <referenceId>26667485</referenceId>
            <title>A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib.</title>
            <authors>Lee J, Sun J, Lim S, Kim H, Yoo K, Jung K, Song H, Ku B, Koh J, Bae Y, Lee S, Ahn J, Park K, Ahn M</authors>
            <journal>Clinical cancer research : an official journal of the American Association for Cancer Research</journal>
            <issue></issue>
            <page></page>
            <year>2015</year>
        </reference>
        <reference>
            <referenceId>22285168</referenceId>
            <title>Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.</title>
            <authors>Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez J, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno M, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez J, Sanchez J, Molina M, Taron M, Paz-Ares L</authors>
            <journal>The lancet oncology</journal>
            <issue>3</issue>
            <page>239-46</page>
            <year>2012</year>
        </reference>
        <reference>
            <referenceId>26648997</referenceId>
            <title>Correlation between expression of epidermal growth factor receptor and adverse reactions after chemotherapy of advanced non-small-cell lung cancer.</title>
            <authors>Hao Z, Tian C, Yang F, Zhang J</authors>
            <journal>Pakistan journal of medical sciences</journal>
            <issue>5</issue>
            <page>1115-20</page>
            <year>2015</year>
        </reference>
        <reference>
            <referenceId>IASLC 2015, Abstract 943</referenceId>
            <title>AZD9291 in Pre-Treated T790M Positive Advanced NSCLC: AURA Study Phase II Extension Cohort</title>
            <authors>Yang JC, Ahn M, Ramalingam SS et al.</authors>
            <journal>J Thor Oncol</journal>
            <issue></issue>
            <page></page>
            <year>2015</year>
        </reference>
        <reference>
            <referenceId>20608935</referenceId>
            <title>Protein overexpression and gene amplification of epidermal growth factor receptor in adult testicular germ cell tumors: potential role in tumor progression.</title>
            <authors>Miyai K, Yamamoto S, Asano T, Tamai S, Matsubara O, Tsuda H</authors>
            <journal>Cancer science</journal>
            <issue>9</issue>
            <page>1970-6</page>
            <year>2010</year>
        </reference>
        <reference>
            <referenceId>17463250</referenceId>
            <title>MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.</title>
            <authors>Engelman J, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park J, Lindeman N, Gale C, Zhao X, Christensen J, Kosaka T, Holmes A, Rogers A, Cappuzzo F, Mok T, Lee C, Johnson B, Cantley L, Jänne P</authors>
            <journal>Science (New York, N.Y.)</journal>
            <issue>5827</issue>
            <page>1039-43</page>
            <year>2007</year>
        </reference>
        <reference>
            <referenceId>16187797</referenceId>
            <title>Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.</title>
            <authors>Greulich H, Chen T, Feng W, Jänne P, Alvarez J, Zappaterra M, Bulmer S, Frank D, Hahn W, Sellers W, Meyerson M</authors>
            <journal>PLoS medicine</journal>
            <issue>11</issue>
            <page>e313</page>
            <year>2005</year>
        </reference>
        <reference>
            <referenceId>ASCO 2013, Abstract 605</referenceId>
            <title>Phase (Ph) I/II study of investigational Aurora A kinase (AAK) inhibitor MLN8237 (alisertib): Updated ph II results in patients (pts) with small cell lung cancer (SCLC), non-SCLC (NSCLC), breast cancer (BrC), head and neck squamous cell carcinoma (HNSCC), and gastroesophageal cancer (GE).</title>
            <authors>Melichar B, Adenis A, Havel L, et al.</authors>
            <journal>J Clin Oncol</journal>
            <issue>31</issue>
            <page></page>
            <year>2013</year>
        </reference>
        <reference>
            <referenceId>20068085</referenceId>
            <title>Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report.</title>
            <authors>Girard N, Lou E, Azzoli C, Reddy R, Robson M, Harlan M, Orlow I, Yatabe Y, Nafa K, Ladanyi M, Viale A, Kris M, Riely G, Miller V, Klein R, Matsuo K, Pao W</authors>
            <journal>Clinical cancer research : an official journal of the American Association for Cancer Research</journal>
            <issue>2</issue>
            <page>755-63</page>
            <year>2010</year>
        </reference>
        <reference>
            <referenceId>25512615</referenceId>
            <title>p53 Mutation Directs AURKA Overexpression via miR-25 and FBXW7 in Prostatic Small Cell Neuroendocrine Carcinoma.</title>
            <authors>Li Z, Sun Y, Chen X, Squires J, Nowroozizadeh B, Liang C, Huang J</authors>
            <journal>Molecular cancer research : MCR</journal>
            <issue></issue>
            <page></page>
            <year>2014</year>
        </reference>
        <reference>
            <referenceId>16014883</referenceId>
            <title>Erlotinib in lung cancer - molecular and clinical predictors of outcome.</title>
            <authors>Tsao M, Sakurada A, Cutz J, Zhu C, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, Marrano P, da Cunha Santos G, Lagarde A, Richardson F, Seymour L, Whitehead M, Ding K, Pater J, Shepherd F</authors>
            <journal>The New England journal of medicine</journal>
            <issue>2</issue>
            <page>133-44</page>
            <year>2005</year>
        </reference>
        <reference>
            <referenceId>26768165</referenceId>
            <title>Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.</title>
            <authors>Ramalingam S, O'Byrne K, Boyer M, Mok T, Jänne P, Zhang H, Liang J, Taylor I, Sbar E, Paz-Ares L</authors>
            <journal>Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</journal>
            <issue>3</issue>
            <page>423-9</page>
            <year>2016</year>
        </reference>
        <reference>
            <referenceId>AACR 2016, Abstract 4834</referenceId>
            <title>Preclinical analysis of the Notch gamma secretase inhibitor BMS-906024 in combination with chemotherapy in the treatment of lung adenocarcinoma</title>
            <authors>Morgan KM, Lee F, Michaud E, et al.</authors>
            <journal>Cancer Res</journal>
            <issue>14 Suppl</issue>
            <page>Abstract nr 4834</page>
            <year>2016</year>
        </reference>
        <reference>
            <referenceId>26362141</referenceId>
            <title>EGFR mutation status in Middle Eastern patients with non-squamous non-small cell lung carcinoma: A single institution experience.</title>
            <authors>Naderi S, Ghorra C, Haddad F, Kourie H, Rassy M, El Karak F, Ghosn M, Abadjian G, Kattan J</authors>
            <journal>Cancer epidemiology</journal>
            <issue></issue>
            <page></page>
            <year>2015</year>
        </reference>
        <reference>
            <referenceId>17510392</referenceId>
            <title>EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity.</title>
            <authors>Vikis H, Sato M, James M, Wang D, Wang Y, Wang M, Jia D, Liu Y, Bailey-Wilson J, Amos C, Pinney S, Petersen G, de Andrade M, Yang P, Wiest J, Fain P, Schwartz A, Gazdar A, Gaba C, Rothschild H, Mandal D, Kupert E, Seminara D, Viswanathan A, Govindan R, Minna J, Anderson M, You M</authors>
            <journal>Cancer research</journal>
            <issue>10</issue>
            <page>4665-70</page>
            <year>2007</year>
        </reference>
        <reference>
            <referenceId>22773520</referenceId>
            <title>Molecular pathways: context-dependent approaches to Notch targeting as cancer therapy.</title>
            <authors>Egloff A, Grandis J</authors>
            <journal>Clinical cancer research : an official journal of the American Association for Cancer Research</journal>
            <issue>19</issue>
            <page>5188-95</page>
            <year>2012</year>
        </reference>
        <reference>
            <referenceId>24222160</referenceId>
            <title>High-throughput molecular genotyping for small biopsy samples in advanced non-small cell lung cancer patients.</title>
            <authors>Maeng C, Lee H, Kim Y, Choi M, Hong J, Jung H, Lee K, Kim H, Kwon O, Sun J, Ahn J, Park K, Um S, Ahn M</authors>
            <journal>Anticancer research</journal>
            <issue>11</issue>
            <page>5127-33</page>
            <year>2013</year>
        </reference>
        <reference>
            <referenceId>24012411</referenceId>
            <title>Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinoma.</title>
            <authors>Watanabe S, Sone T, Matsui T, Yamamura K, Tani M, Okazaki A, Kurokawa K, Tambo Y, Takato H, Ohkura N, Waseda Y, Katayama N, Kasahara K</authors>
            <journal>Lung cancer (Amsterdam, Netherlands)</journal>
            <issue>2</issue>
            <page>370-2</page>
            <year>2013</year>
        </reference>
        <reference>
            <referenceId>27198353</referenceId>
            <title>LBA2_PR: Osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results.</title>
            <authors>Yang J, Ramalingam S, Jänne P, Cantarini M, Mitsudomi T</authors>
            <journal>Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</journal>
            <issue>4 Suppl</issue>
            <page>S152-3</page>
            <year>2016</year>
        </reference>
        <reference>
            <referenceId>24495481</referenceId>
            <title>Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer.</title>
            <authors>Ma X, Rousseau V, Sun H, Lantuejoul S, Filipits M, Pirker R, Popper H, Mendiboure J, Vataire A, Le Chevalier T, Soria J, Brambilla E, Dunant A, Hainaut P</authors>
            <journal>Molecular oncology</journal>
            <issue></issue>
            <page></page>
            <year>2014</year>
        </reference>
        <reference>
            <referenceId>24263064</referenceId>
            <title>First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study.</title>
            <authors>Douillard J, Ostoros G, Cobo M, Ciuleanu T, McCormack R, Webster A, Milenkova T</authors>
            <journal>British journal of cancer</journal>
            <issue>1</issue>
            <page>55-62</page>
            <year>2014</year>
        </reference>
        <reference>
            <referenceId>20811949</referenceId>
            <title>Comparison of p53 and epidermal growth factor receptor gene status between primary tumors and lymph node metastases in non-small cell lung cancers.</title>
            <authors>Chang Y, Wu C, Shih J, Lee Y</authors>
            <journal>Annals of surgical oncology</journal>
            <issue>2</issue>
            <page>543-50</page>
            <year>2011</year>
        </reference>
        <reference>
            <referenceId>22490401</referenceId>
            <title>Correlation of epidermal growth factor receptor overexpression with increased epidermal growth factor receptor gene copy number in esophageal squamous cell carcinomas.</title>
            <authors>Yang Y, Xu K, Zhou Y, Gao X, Chen L</authors>
            <journal>Chinese medical journal</journal>
            <issue>3</issue>
            <page>450-4</page>
            <year>2012</year>
        </reference>
        <reference>
            <referenceId>26359571</referenceId>
            <title>FDG Uptake in Non-Small Cell Lung Cancer Is Not an Independent Predictor of EGFR or KRAS Mutation Status: A Retrospective Analysis of 206 Patients.</title>
            <authors>Lee S, Bae S, Jung S, Kim C</authors>
            <journal>Clinical nuclear medicine</journal>
            <issue></issue>
            <page></page>
            <year>2015</year>
        </reference>
        <reference>
            <referenceId>20353893</referenceId>
            <title>Concordance between epidermal growth factor receptor status in primary non-small-cell lung cancer and metastases: a post-mortem study.</title>
            <authors>Watzka S, Rauscher-Pötsch I, Nierlich P, Setinek U, Köstler W, Pötschger U, Müller M, Attems J</authors>
            <journal>European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery</journal>
            <issue>1</issue>
            <page>34-7</page>
            <year>2010</year>
        </reference>
        <reference>
            <referenceId>15920544</referenceId>
            <title>EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations.</title>
            <authors>Bhargava R, Gerald W, Li A, Pan Q, Lal P, Ladanyi M, Chen B</authors>
            <journal>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc</journal>
            <issue>8</issue>
            <page>1027-33</page>
            <year>2005</year>
        </reference>
        <reference>
            <referenceId>21177375</referenceId>
            <title>ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action.</title>
            <authors>Fletcher G, Brokx R, Denny T, Hembrough T, Plum S, Fogler W, Sidor C, Bray M</authors>
            <journal>Molecular cancer therapeutics</journal>
            <issue>1</issue>
            <page>126-37</page>
            <year>2011</year>
        </reference>
        <reference>
            <referenceId>24091768</referenceId>
            <title>AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53.</title>
            <authors>Kalous O, Conklin D, Desai A, Dering J, Goldstein J, Ginther C, Anderson L, Lu M, Kolarova T, Eckardt M, Langerød A, Børresen-Dale A, Slamon D, Finn R</authors>
            <journal>Breast cancer research and treatment</journal>
            <issue>3</issue>
            <page>397-408</page>
            <year>2013</year>
        </reference>
        <reference>
            <referenceId>25956936</referenceId>
            <title>CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer.</title>
            <authors>Rizzo S, Petrella F, Buscarino V, De Maria F, Raimondi S, Barberis M, Fumagalli C, Spitaleri G, Rampinelli C, De Marinis F, Spaggiari L, Bellomi M</authors>
            <journal>European radiology</journal>
            <issue></issue>
            <page></page>
            <year>2015</year>
        </reference>
        <reference>
            <referenceId>17470858</referenceId>
            <title>Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.</title>
            <authors>Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon J, Van Laethem J, Maurel J, Richardson G, Wolf M, Amado R</authors>
            <journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal>
            <issue>13</issue>
            <page>1658-64</page>
            <year>2007</year>
        </reference>
        <reference>
            <referenceId>21087899</referenceId>
            <title>Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics.</title>
            <authors>Ma C, Janetka J, Piwnica-Worms H</authors>
            <journal>Trends in molecular medicine</journal>
            <issue>2</issue>
            <page>88-96</page>
            <year>2011</year>
        </reference>
        <reference>
            <referenceId>25913131</referenceId>
            <title>PI3K/mTOR pathway inhibition overcomes radioresistance via suppression of the HIF1-α/VEGF pathway in endometrial cancer.</title>
            <authors>Miyasaka A, Oda K, Ikeda Y, Sone K, Fukuda T, Inaba K, Makii C, Enomoto A, Hosoya N, Tanikawa M, Uehara Y, Arimoto T, Kuramoto H, Wada-Hiraike O, Miyagawa K, Yano T, Kawana K, Osuga Y, Fujii T</authors>
            <journal>Gynecologic oncology</journal>
            <issue></issue>
            <page></page>
            <year>2015</year>
        </reference>
        <reference>
            <referenceId>20349288</referenceId>
            <title>Maspin, VEGF and p53 expression in small biopsies of primary advanced lung cancer and relationship with clinicopathologic parameters.</title>
            <authors>Bircan A, Bircan S, Kapucuoglu N, Songur N, Ozturk O, Akkaya A</authors>
            <journal>Pathology oncology research : POR</journal>
            <issue>4</issue>
            <page>553-61</page>
            <year>2010</year>
        </reference>
        <reference>
            <referenceId>22228822</referenceId>
            <title>The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor.</title>
            <authors>Kim Y, Ko J, Cui Z, Abolhoda A, Ahn J, Ou S, Ahn M, Park K</authors>
            <journal>Molecular cancer therapeutics</journal>
            <issue>3</issue>
            <page>784-91</page>
            <year>2012</year>
        </reference>
        <reference>
            <referenceId>21502435</referenceId>
            <title>Adenosquamous carcinoma of the lung: a microdissection study of KRAS and EGFR mutational and amplification status in a western patient population.</title>
            <authors>Tochigi N, Dacic S, Nikiforova M, Cieply K, Yousem S</authors>
            <journal>American journal of clinical pathology</journal>
            <issue>5</issue>
            <page>783-9</page>
            <year>2011</year>
        </reference>
        <reference>
            <referenceId>2259385</referenceId>
            <title>Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome.</title>
            <authors>Srivastava S, Zou Z, Pirollo K, Blattner W, Chang E</authors>
            <journal>Nature</journal>
            <issue>6303</issue>
            <page>747-9</page>
            <year>1991</year>
        </reference>
        <reference>
            <referenceId>18410249</referenceId>
            <title>Structural biology of the tumor suppressor p53.</title>
            <authors>Joerger A, Fersht A</authors>
            <journal>Annual review of biochemistry</journal>
            <issue></issue>
            <page>557-82</page>
            <year>2008</year>
        </reference>
        <reference>
            <referenceId>24736066</referenceId>
            <title>Hereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutations.</title>
            <authors>Gazdar A, Robinson L, Oliver D, Xing C, Travis W, Soh J, Toyooka S, Watumull L, Xie Y, Kernstine K, Schiller J</authors>
            <journal>Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</journal>
            <issue>4</issue>
            <page>456-63</page>
            <year>2014</year>
        </reference>
        <reference>
            <referenceId>19096299</referenceId>
            <title>EGFR T790M mutation: a double role in lung cancer cell survival?</title>
            <authors>Suda K, Onozato R, Yatabe Y, Mitsudomi T</authors>
            <journal>Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</journal>
            <issue>1</issue>
            <page>1-4</page>
            <year>2009</year>
        </reference>
        <reference>
            <referenceId>19935675</referenceId>
            <title>Awakening guardian angels: drugging the p53 pathway.</title>
            <authors>Brown C, Lain S, Verma C, Fersht A, Lane D</authors>
            <journal>Nature reviews. Cancer</journal>
            <issue>12</issue>
            <page>862-73</page>
            <year>2009</year>
        </reference>
        <reference>
            <referenceId>19692680</referenceId>
            <title>Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.</title>
            <authors>Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang J, Chewaskulyong B, Jiang H, Duffield E, Watkins C, Armour A, Fukuoka M</authors>
            <journal>The New England journal of medicine</journal>
            <issue>10</issue>
            <page>947-57</page>
            <year>2009</year>
        </reference>
        <reference>
            <referenceId>21799033</referenceId>
            <title>MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.</title>
            <authors>Bridges K, Hirai H, Buser C, Brooks C, Liu H, Buchholz T, Molkentine J, Mason K, Meyn R</authors>
            <journal>Clinical cancer research : an official journal of the American Association for Cancer Research</journal>
            <issue>17</issue>
            <page>5638-48</page>
            <year>2011</year>
        </reference>
        <reference>
            <referenceId>18247017</referenceId>
            <title>Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas.</title>
            <authors>Senderowicz A, Johnson J, Sridhara R, Zimmerman P, Justice R, Pazdur R</authors>
            <journal>Oncology (Williston Park, N.Y.)</journal>
            <issue>14</issue>
            <page>1696-706; discussion 1706-9, 1712, 1715</page>
            <year>2007</year>
        </reference>
        <reference>
            <referenceId>25923549</referenceId>
            <title>AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.</title>
            <authors>Jänne P, Yang J, Kim D, Planchard D, Ohe Y, Ramalingam S, Ahn M, Kim S, Su W, Horn L, Haggstrom D, Felip E, Kim J, Frewer P, Cantarini M, Brown K, Dickinson P, Ghiorghiu S, Ranson M</authors>
            <journal>The New England journal of medicine</journal>
            <issue>18</issue>
            <page>1689-99</page>
            <year>2015</year>
        </reference>
        <reference>
            <referenceId>24696321</referenceId>
            <title>Nondisruptive p53 mutations are associated with shorter survival in advanced non-small-cell lung cancer patients.</title>
            <authors>Molina-Vila M, Bertran-Alamillo J, Gasco A, Mayo-de-Las-Casas C, Sanchez-Ronco M, Pujantell-Pastor L, Bonanno L, Favaretto A, Cardona A, Vergnenegre A, Majem M, Massuti B, Morán T, Carcereny E, Viteri S, Rosell R</authors>
            <journal>Clinical cancer research : an official journal of the American Association for Cancer Research</journal>
            <issue></issue>
            <page></page>
            <year>2014</year>
        </reference>
        <reference>
            <referenceId>27071706</referenceId>
            <title>Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer.</title>
            <authors>Wang S, Cang S, Liu D</authors>
            <journal>Journal of hematology &amp; oncology</journal>
            <issue></issue>
            <page>34</page>
            <year>2016</year>
        </reference>
        <reference>
            <referenceId>24982341</referenceId>
            <title>A combined lymphokine-activated killer (LAK) cell immunotherapy and adenovirus-p53 gene therapy for head and neck squamous cell carcinoma.</title>
            <authors>Saito H, Ando S, Morishita N, Lee K, Dator D, Dy D, Shigemura K, Adhim Z, Nibu K, Fujisawa M, Shirakawa T</authors>
            <journal>Anticancer research</journal>
            <issue>7</issue>
            <page>3365-70</page>
            <year>2014</year>
        </reference>
        <reference>
            <referenceId>27673365</referenceId>
            <title>Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib.</title>
            <authors>Courtin A, Smyth T, Hearn K, Saini H, Thompson N, Lyons J, Wallis N</authors>
            <journal>British journal of cancer</journal>
            <issue>9</issue>
            <page>1069-1077</page>
            <year>2016</year>
        </reference>
        <reference>
            <referenceId>23916913</referenceId>
            <title>Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.</title>
            <authors>Xie M, He C, Wei S, Zhang L</authors>
            <journal>European journal of cancer (Oxford, England : 1990)</journal>
            <issue>16</issue>
            <page>3559-72</page>
            <year>2013</year>
        </reference>
        <reference>
            <referenceId>21825264</referenceId>
            <title>Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study.</title>
            <authors>Fouladi M, Stewart C, Olson J, Wagner L, Onar-Thomas A, Kocak M, Packer R, Goldman S, Gururangan S, Gajjar A, Demuth T, Kun L, Boyett J, Gilbertson R</authors>
            <journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal>
            <issue>26</issue>
            <page>3529-34</page>
            <year>2011</year>
        </reference>
    </references>
    <testSite>
        <name>Guardant Health</name>
        <clia>05D2070300</clia>
        <cap>8765297</cap>
        <director>Arthur Baca, MD PhD</director>
        <address>
            <address1>505 Penobscot Drive</address1>
            <city>Redwood City</city>
            <state>CA</state>
            <country>United States</country>
            <postalCode>94063</postalCode>
        </address>
    </testSite>
    <alterationDetected>true</alterationDetected>
    <clinicallySignificant>true</clinicallySignificant>
    <tx>true</tx>
    <status>FINAL</status>
    <timepoint>2</timepoint>
    <number>2</number>
    <compatibility>17.0</compatibility>
    <collectionDate>2018-02-01</collectionDate>
    <receiveDate>2018-02-05</receiveDate>
    <accessionDate>2018-02-06</accessionDate>
    <reportDate>2018-02-12</reportDate>
    <reportRevisionDate>2018-02-12</reportRevisionDate>
</report>
